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Growth hormone (GH) is released in a pulsatile fashion from the anterior pituitary 
gland, with the greatest release occurring during sleep and exercise.  Under normal 
conditions, nocturnal GH release is attenuated during sleep deprivation.  Acute sleep 
deprivation can also impair exercise performance and cognitive function.  Therefore, the 
primary purpose of this study was to assess the impact of acute sleep deprivation on 
exercise-induced GH release. Secondary aims were to investigate alterations in exercise 
performance and cognitive function during acute sleep deprivation.  Ten male subjects 
(20.6 ± 1.4 years) were screened for normal sleeping patterns before completing two 
randomized 24-hour laboratory sessions.  They completed a brief, high-intensity exercise 
bout following either a night of adequate sleep (SLEEP) or acute (24-hour) sleep 
deprivation (SLD).  Anaerobic performance (mean power [MP], peak power [PP], time to 
peak power [TTPP], minimum power [MinP], fatigue index [FI] and total work per sprint 
[TWPS]) was determined from four maximal 30-sec Wingate sprints on a cycle 
ergometer followed by four minutes of active recovery between each sprint.  Subjects 
also performed psychomotor vigilance tasks (PVT) and Paced Auditory Serial Addition 
Tests (PASAT) during each 24-hr session (0800h, 2000h, 0600h and 0730h) with the 
latter two taken immediately pre- and post-exercise.   The average amount of sleep in the 
7 days prior to each session was similar between the SLEEP and SLD sessions (7.92 ± 
0.33 vs. 7.98 ± 0.39 hr, p = 0.656, respectively) and during the actual SLEEP session in 
the lab, the total amount of sleep was similar to the 7 days leading up to the lab session 
	  
	   	  
(7.72 ± 0.14 hours vs. 7.92 ± 0.33 hours, respectively) (p = 0.166).  Repeated measures 
analysis of variance (ANOVA) revealed a significant interaction effect of sprint x session 
on PP (p < 0.05).   Only the peak power output during sprint 1 of the SLEEP vs. SLD 
session was significantly greater (1207 ± 177 vs. 1150 ± 137 W, respectively, p < 0.01).  
MP, PP, MinP and TWPS decreased significantly within each session (p < 0.01), but 
there were no significant main effects of session.  Respiratory rate (RR) was significantly 
elevated at rest during the SLD vs. SLEEP session (14.8 ± 2.2 vs. 13.7 ± 3.2 breaths/min, 
p < 0.05) while heart rate (HR) was significantly depressed at rest (60 ± 8 vs. 64 ± 8 bpm, 
p < 0.05) and during exercise (176 ± 9 vs. 182 ± 9 bpm, p < 0.05).  Average oxygen 
consumption (VO2), metablic equivalent (METS), expired carbon dioxide (VCO2), 
ventilation (VE), respiratory exchange ratio (RER), respiratory rate (RR), tidal volume 
(VT), peak VO2 and peak METS were all similar between sessions.  Resting GH 
concentration and time to reach exercise-induced peak GH concentration were similar 
between the SLEEP and SLD sessions (0.57 ± 0.13 vs. 1.35 ± 0.55 µg/L, p = 0.575; 29.5 
± 2.2 vs. 27.0 ± 1.5 min, p = 0.257, respectively).  However, GH AUC (exercise + 
recovery), peak GH concentration and ΔGH (peak GH – resting GH) were significantly 
lower during the SLEEP session (p < 0.01).  PVT scores post-exercise were significantly 
poorer during the SLD session (326.2 ± 36.6 vs. 298.8 ± 21.1 msec, p < 0.05).  In 
conclusion, acute sleep deprivation influenced exercise-induced peak HR and GH but had 
minimal effects on exercise performance.  Furthermore, sleep deprivation had no effect 
on cognitive measures at rest, but did impair sensory sensitivity following exercise.   
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CHAPTER I 
 
INTRODUCTION 
 
 
Statement of Problem 
Humans spend approximately one-third of their lives sleeping (176) and sleep is 
an integral component of mental and physical performance.  Athletic and occupational 
requirements challenge modern day sleep management.   Athletes and coaches believe 
that sleep is essential for peak physical and mental performance.  Additionally, 
occupational demands may force an altered sleep schedule that may affect the 
hypothalamic-pituitary axis leading to a de-synchronization of hormonal efflux.  Growth 
hormone (GH) is secreted in a pulsatile fashion with the highest concentrations occurring 
during sleep (115, 202, 221, 240, 261) and exercise (40, 45, 76, 89, 211-213, 237, 287-
288, 293-296).  GH has been a focus of attention for many studies; however, limited 
evidence explains the effect of sleep deprivation on exercise-induced growth hormone 
release.  In sleep deprivation studies, normal GH nocturnal release is attenuated and in 
some cases, absent (36, 39, 131, 221, 240).  Therefore, investigating the effect of exercise 
performance and subsequent release of GH, to acute sleep deprivation will increase our 
understanding of how exercise performance may be impaired and how exercise can 
influence total GH release in the sleep-deprived population.  The long-term goal of this 
research is to determine what particular forms of exercise and/or cognition are affected 
by sleep deprivation and how exercise can be used during sleep deprivation to re-
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synchronize hormonal regulation responsible for mediating many of the body’s important 
metabolic demands.   
Our primary hypothesis is that exercise-induced peak GH and GH AUC will be 
augmented following acute sleep deprivation.  We base our hypothesis on the 
documented attenuation of GH release during sleep deprivation (36, 39, 131, 221, 240) 
but also on the fact that exercise has been shown to be powerful enough to override the 
naturally occurring cyclic downregulation in GH release controlled by circadian rhythm 
(85, 128, 255). We believe that exercise is a very powerful stimulus that can augment GH 
release by overriding the mechanistic inhibitions caused by sleep deprivation. Our 
approach will be to sleep-deprive subjects for 24-hours and then use an acute bout of 
exercise to measure GH release.  
Our secondary hypotheses are that sleep deprivation will decrease exercise 
performance without changing cardiorespiratory response to exercise and that exercise 
can be used to restore cognitive function following sleep deprivation.  We base our 
secondary hypotheses on previously reported literature indicating little change occurs in 
anaerobic exercise following sleep deprivation (107, 177, 227, 238, 241, 268).  However, 
we believe that using a “supramaximal” anaerobic exercise protocol that employs 
repetitive bouts to exhaustion is more similar to a real athletic event and performance will 
be decreased due to a greater workload completed by our subjects compared to the 
aforementioned studies employing similar anaerobic testing protocols with less total 
required workloads.  Literature on the effect of sleep deprivation on the cardiorespiratory 
response to exercise is equivocal, likely due to the use of varying exercise protocols and 
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experimental designs (22, 165, 179, 207, 247, 305).  However, we assume that the 
cardiorespiratory responses to our anaerobic exercise protocol will not be influenced by 
sleep deprivation because of the significant reliance on the ATP-PC energy system in this 
type of sprint activity.  We will examine the counterbalancing effects of exercise during 
sleep deprivation on cognitive performance restoration by using two cognition tests that 
measure psychomotor sensory sensitivity and cognitive processing function.  Our 
approach will employ these tests at several different time points during each session so 
that baseline, immediate pre- and post-exercise measurements can be obtained.  We base 
our hypothesis that exercise during sleep deprivation will improve cognitive performance 
because exercise has been shown to increase the speed of motor processes and hyper-
activate the link between external arousal and neural activation (161, 247).  
Aims and Hypotheses 
We will test our hypotheses by pursuing the following aims: 
Aim 1:  To determine if sleep deprivation influences exercise-induced growth hormone 
AUC and peak GH concentration  
Working hypotheses: In response to sleep deprivation compared to a night of 
adequate rest 1) resting GH release will not change, 2) exercise induced peak GH 
concentration will increase, and 3) exercise-induced GH AUC will increase.   
Aim 2:  To determine if sleep deprivation influences exercise performance  
Working hypotheses: In response to sleep deprivation compared to a night of 
adequate rest 1) peak anaerobic power will decrease, 2) mean anaerobic power will 
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decrease, 3) minimum anaerobic power will decrease, 4) total work completed will 
decrease, and 5) fatigue index will increase.  
Aim 3:  To determine if sleep deprivation influences cardiorespiratory response  
to rest and exercise  
Working hypotheses: In response to sleep deprivation compared to a night of   
adequate rest, resting and exercise-induced peak HR, VO2, VCO2, RER, RR, VE, VT and 
RPE will not change. 
Aim 4:  To determine the interaction of sleep deprivation and exercise on  
cognitive performance  
Working hypotheses:  Sleep deprivation will 1) decrease sensory sensitivity and  
cognitive processing function at rest, 2) be counteracted by exercise so that sensory 
sensitivity and cognitive processing function will be similar to following a night of 
adequate rest.  
 Identifying the influence of sleep deprivation on exercise-induced GH 
concentration may aid in re-synching the hormonal desensitization that occurs in sleep-
deprived subjects.   Additionally, understanding the influence of sleep deprivation on 
high-intensity exercise and reaction time will also help guide coaches and athletes with 
optimal performance and training regimes.  Finally, our results could provide 
occupationally-related sleep-deprived individuals a feasible alternative (short-term 
exercise) to restore cognitive function.  
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CHAPTER II 
 
REVIEW OF LITERATURE 
 
 
The following review of literature will address two general topic areas:  1) growth 
hormone (GH) physiology, regulation, biological effects, and the effects of age, body 
composition, diet and fitness on 24-hour and acute exercise-induced GH release and 2) 
the effects of circadian rhythm and sleep on basal and exercise-induced GH release.  
Growth Hormone (GH) Physiology & Regulation 
GH Molecular Variants 
Human growth hormone is one of the seven-peptide hormones produced and 
secreted from the anterior lobe of the pituitary gland.  GH gene expression is strongly 
dependent on pituitary-specific transcription factor-1 (Pit-1) expressed in somatotrope 
cells of the pituitary gland (30).  The GH molecule represents a family of different 
proteins derived from a single gene (chromosome 17) and over 100 isoforms in 
circulation have been reported, most displaying similar characteristics (22, 189, 293).  
Although most GH molecular isoforms are formulated and secreted from the pituitary 
gland, they can undergo post-translational modification to change their biological action 
through the addition of other biochemical functional groups (59).  The molecular sizes of 
the GH isoforms vary from large molecular-weight GH isoforms that result from the 
formation of hetero- or homodimers and/or oligomers, intermediate molecular-weight and 
low molecular-weight isoforms.  Alternative splicing of exon 3 results in a smaller 176-
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amino acid 20-kDa molecular isoform, which lacks residues 32-46 and approximately 
10% of the circulating form of GH is 20-kD.  Initially, GH 20-kDa was deemed incapable 
of producing any biological activity due to the change in its tertiary structure altering GH 
receptor binding, but studies have shown it has subsequent agonistic action paralleling 
the 22-kDa form primarily in adipose tissue (280) and hepatocytes (104).  Smaller 
molecular-weight fragments are manufactured from residues 1-43 and 44-191 and 
comprise 5- and 17-kDa fragments as well.  Many other molecular isoforms have been 
identified, and their biological capabilities are still to be determined (22, 188), yet each 
GH molecular isoform may be capable of causing different physiological functions (151, 
189).  However, the most abundant, biologically active and studied GH isoform is the 1-
191 amino acid 22-kDa GH molecule (59, 188).   
Role of the GH Receptor 
The GH receptor (GHR) is most abundant in the liver but receptors are widely 
expressed in adipose tissue, muscle, kidney, heart and brain (168, 226) and are highly 
targeted by their ligand growth hormone (90, 150, 281). After dimerizing the GH receptor 
and creating a conformational change in the extracellular domain, the receptor activates 
Janus Kinase 2 (JAK2), a tyrosine kinase complex involved in intracellular downstream 
signaling that eventually results in up regulation of GH-dependent gene transcription and 
IGF-1 expression (10, 38).  The 620-amino acid receptor consists of an extracellular 
domain of 246 amino acids that has a sequence identity with growth hormone-binding 
protein (GHBP).  The GHR also has a single transmembrane domain consisting of 24 
amino acids and a cytoplasmic domain consisting of 350 amino acids.  Of the nine coding 
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exons that constitute the receptor gene, exons 3-7 encode the extracellular domain (68).  
Two distinct isoforms of the receptor exist, the full-length isoform and an isoform that 
lacks exon 3 (d3-GHR), which is specific to humans.  The isoforms are not likely formed 
from alternative splicing per se, but by a homologous recombinant event that occurs 
between retroviral elements surrounding exon 3 in the GHR gene (200).  Most studies 
report that both isoforms have similar binding properties and functionality in humans 
(133, 226, 257), although in vitro studies have reported up-regulated STAT5 signaling 
with activation of the d3-GHR isoform.  Dos Santos et al. (68) reported that the d3-GHR 
isoform induced a greater transcriptional activity than the full-length isoform in vitro in a 
dose-dependent manner across a broad GH stimulation range (0 to 50 ng/ml).  It has been 
suggested that removal of the N-terminal loop encoded by exon 3 (residues 7-32) can 
facilitate small conformational changes in the extracellular domain enhancing receptor 
activity, which allows it to parallel the biological activity of the full length GHR isoform 
(200) 
Role of GH Binding Protein (GHBP) 
Growth-hormone binding proteins of high and low affinity have been identified in 
human plasma.  The low-affinity GHBP is unrelated to the GHR but the high-affinity 
GHBP regulates GH bioactivity in tissues through its influence on GH availability and 
competition with the GHR for GH (17, 20, 23-24).  The high affinity-GHBP is produced 
through proteolytic cleavage of the extracellular domain of the GH receptor at the cell 
surface (21, 55, 150) and since the majority of GH receptors are housed in the liver, most 
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GHBP is located there as well (168).  High-affinity GHBP forms a GH-GHBP complex 
in plasma and 30-50% of circulating plasma GH is bound by the high-affinity GHBP 
under basal conditions.  However, this can change rapidly coinciding with fluctuations in 
plasma GH levels.  The level of plasma GHBP is inversely related to the GH 
concentration and the percentage of GH bound to GHBP can vary from 10% to 80% over 
a 24-hour period (17, 23, 271).  The high-affinity GH-GHBP complexes act as a reservoir 
to prevent plasma GH concentrations from falling to zero during the oscillatory bursts of 
the pulsatile GH pattern.   By doing so, the GH-GHBP complex also prolongs GH half-
life (~19 minutes) compared to free GH (~7 minutes) and slows GH clearance 10-fold 
(20, 271).  The kidney is primarily responsible for clearing up to 60-70% of GH with 
other less significant clearance coming from the GHR (98).  
GHBP displays inter-individual variation as well as tissue specificity and GH 
administration is known to have varying effects on regulating plasma GHBP levels, likely 
due to various populations and methods utilized as well as type of tissue examined (109, 
113, 246). Females have higher concentrations of GHBP compared to males and this is 
likely due to having higher resting GH levels but less marked GH pulsatility (18, 113). 
GHBP is also known to decrease with age and may be inversely related to increases in 
body mass (20, 167, 209).  Although the ratio of GHBP to GHR production is variable 
and tissue specific (119), plasma GHBP can provide an index of GHR expression in the 
liver and is used as a measure of the GH bioavailability (17).   
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Role of the Hypothalamic-Pituitary Axis 
Human growth hormone is secreted in a pulsatile manner from the anterior 
pituitary gland.  The rate of change in plasma GH concentrations is controlled in an 
endocrine and exocrine fashion by its secretion rate and elimination kinetics (183).  More 
specifically, GH secretion is mediated at (least two-fold) by the interplay of two peptides 
released from the neurosecretory nuclei of the hypothalamus:  growth hormone releasing 
hormone (GHRH) and somatostatin (SMS) (74, 276).  The release of these peptides into 
the hypophyseal portal venous blood surrounding the pituitary is time-delayed and 
necessary to sustain pulsatile GH secretion through amplification and suppression at the 
hypothalamic-pituitary axis (245, 270).  These peptides act concomitantly through a 
network of independent and synergistic mechanisms to facilitate the subsequent 
biological effects of GH.   In addition, GH secretion is modulated by additional 
hypothalamic and peripheral factors that facilitate a balanced integration of feedback 
signals to the pituitary gland.  These include insulin-like growth factor-1 (IGF-1) and a 
growth hormone secretagogue known as ghrelin (growth hormone-releasing peptide 
[GHRP]).  Ghrelin acts synergistically with GHRH, while GHRH and SMS act 
antagonistically to regulate GH secretion from the hypothalamus, which in turn affects 
GH release from the anterior lobe of the pituitary gland (276).  Under normal conditions, 
GH secretion is depressed in the presence of increased SMS or decreased GHRH (248).  
Classic studies in male rats have proven the reciprocal relationship wherein GHRH and 
SMS are secreted alternately to stimulate and inhibit the secretion of GH (206, 245).  
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Somatostatin (SMS) 
SMS acts as a universal inhibitor and regulator of endocrine and exocrine 
secretions in most tissues of the body.  SMS interacts with endocrine tissues such as the 
pituitary, pancreas, liver, gastrointestinal tract (GIT), thyroid, adrenal glands and immune 
system and the central nervous system (mainly the hypothalamus).  There are two active 
forms of SMS, which come from the alternative cleavage of a single prehormone.  The 
14-chain amino acid (SMS-14) makes up 35% of the total SMS content.  SMS-14 has a 
disulfide bridge that creates its cyclic structure and is synthesized in the periventricular 
nucleus (PVN) of the hypothalamus.  Sixty-five percent of the body’s total SMS content 
comes from the other 28-amino acid peptide chain (SMS-28), that is secreted from 
epithelial cells in the GIT where it acts in a paracrine and autocrine fashion and can 
inhibit its own secretion (82).  
Somatostatin receptors are ubiquitously expressed in most tissues and have 
varying biological endpoints depending on location (175).   According to their sequence 
identity, which possesses a 39-57% similarity between receptor subtypes (145), each one 
can be grouped into either SMS1 or SMS2.  SMS1 receptor subtypes (sst-1, -2 and -5) are 
located on the hypothalamus and anterior pituitary gland.  Elevated GH secretion from 
the pituitary into the bloodstream stimulates SMS neurons in the PVN to secrete SMS to 
the pituitary through a neuroendocrine negative feedback mechanism.  SMS released 
from the hypothalamus travels through the portal vein to the pituitary gland and directly 
inhibits GH exocytosis from the pituitary.  It can also indirectly decrease GH release 
from the pituitary through central down-regulation of the GHRH-containing neurons in 
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the hypothalamus as demonstrated by 1) the absence of CNS inhibition of SMS leading to 
increased sensitivity of the GHRH receptor resulting in increased GH gene expression in 
the pituitary (276) and 2) the failure of hypothalamic-administered ghrelin to augment 
GH release through activating the GHRH neurons (279).  Therefore, it has been 
demonstrated that SMS only adjusts the magnitude of basal and pulsatile release patterns 
and therefore, does not initiate spontaneous GH pulse patterns, unlike GHRH whose role 
has been tagged to the initiation of GH pulses (91).  Of the three separate receptors in the 
SMS1 group, sst-2 and -5 likely have the greatest inhibitory effect on GH exocytosis 
(175), although GH synthesis is not influenced by SMS1 receptor activation.  SMS2-
grouped receptor subtypes (sst-3 and -4), have no known linkage to the clinical relevance 
of GH at the present time (203, 225).  Additionally, ghrelin, which has a stimulatory 
effect on GH, is located in the GIT and thus, SMS-28 may be able to indirectly regulate 
GH secretion through binding ghrelin and altering the subsequent biological feedback on 
the hypothalamic-pituitary axis (66, 203, 243).  
GH Releasing Hormone (GHRH) 
GHRH is a 44-amino acid peptide that is released from GH-releasing neurons of 
the arcuate nucleus (ArC), located in the hypothalamus.  In the pituitary, GHRH has 
several trophic effects on GH including the rapid exocytosis of GH-containing secretory 
granules, GH gene transcription, and the expression of ghrelin peptide and its receptors.  
GHRH receptors are found mainly in somatotrope cells of the pituitary gland but are also 
found in the gonads, kidneys, adrenal glands and the central nervous system (CNS) (83).  
Hypothalamic GHRH outflow rather than SMS withdrawal consistently accompanies GH 
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secretion and GHRH is primarily responsible for the initiation of GH secretion from the 
pituitary (64, 91). In contrast, elevated hypothalamic GHRH stimulates SMS secretion 
and auto-inhibition of its own outflow resulting in downstream pituitary GH suppression 
(276). 
GHRH-induced GH release is greatest at night.  In humans, GHRH administered 
during slow-wave sleep (SWS) results in more GH release compared to administration 
during wake or REM sleep.  In contrast, if subjects are kept awake during the biological 
nighttime, GH does not respond to GHRH (260-261).   It is well documented that 
hypothalamic GHRH stimulates non-rapid eye movement sleep (NREMS) and GH (193, 
195, 239).  This has been demonstrated in studies that use somatostatin (to inhibit 
GHRH) resulting in decreased NREMS in humans (78).  GHRH is indirectly involved in 
the promotion of rapid eye movement sleep (REMS) but only through the release of 
pituitary GH as demonstrated by hypophysectomized rats (194) and after GH infusion in 
lit/lit mice that lack a functional GHRH receptor (192).  This is in contrast to Topilla et 
al. (252) that showed SMS mRNA in the hypothalamus is increased during sleep 
deprivation in humans.  This implies that in humans, sleep deprivation will increase SMS 
protein expression and should theoretically decrease GH release, but not necessarily GH 
synthesis.  
Ghrelin (Growth Hormone Releasing Peptide [GHRP])  
Ghrelin (GHRP) is a growth hormone secretagogue (GHS) consisting of a 28-
amino acid peptide produced primarily in the stomach but also to a lesser extent in the 
pituitary, hypothalamus, pancreas, kidneys, immune cells, placenta and testes (264, 276).   
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The post-translational modification of ghrelin, in which one of the 28-amino acids is 
acylated, is essential for the ligand to bind to its receptor and thus execute the majority of 
its biological activity (137, 181).  Double-labeling studies have demonstrated the 
expression of the GHS receptor (GHR-R1a) on GHRH mRNA-containing neurons 
located in the ArC of the hypothalamus (244). The largest proportion of ghrelin receptor 
cells in the hypothalamus is on neuropeptide Y (NPY)-expressing ArC neurons and not 
PVN SMS-expressing neurons (230).   Recently, the ghrelin receptor has been found in 
the vagal afferent neurons suggesting that the vagal afferent system is a major pathway 
exhibiting ghrelin’s effects on GH through the hypothalamus (56).  To a lesser extent, 
ghrelin receptors are also located on somatotrope cells of the pituitary gland (185); and 
ghrelin receptors have been found in other tissues as well (11, 88, 105, 139, 182, 201).  
The majority of ghrelin (80-90%) circulates in the serum in its non-acylated form and has 
no biological effect on GH release (37).   Following acetylation, ghrelin is transported 
from the blood into the CNS where it stimulates pulsatile GH secretion by 1) directly 
binding to the growth hormone secretagogue receptor type 1a (GHS-R1a) and 
depolarizing the somatotroph cell membranes located in the anterior pituitary, 2) directly 
binding to the GHS-R1a on the ArC neurons of the hypothalamus, which markedly 
increases GHS-induced hypothalamic GHRH release and 3) decreasing hypothalamic 
SMS release (4, 11, 95, 116, 121, 137, 242-243).   
Although ghrelin has a positive 2-3-fold effect on GH release under normal 
conditions (11, 33, 137), circulating ghrelin does not increase 24-hour GH in the presence 
of GHRH antagonists suggesting that its actions may be GHRH peptide-dependent (16).  
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In addition, ghrelin is not increased along with GH during insulin-induced hypoglycemia 
(77, 153). Thus, the precise role of ghrelin in the direct stimulation of GH is still 
questionable, especially since the release of ghrelin is pulsatile and more associated with 
food intake than corresponding GH pulses as grehlin increases before meals and is 
suppressed after feeding (50, 250, 254). The majority of GHS receptors in peripheral 
tissues outside the pituitary and hypothalamus are non-specific for ghrelin, which helps 
explain its ubiquitous involvement in its biological activity (182).  Ghrelin has numerous 
central and peripheral effects resulting in the release of prolactin and ACTH, sleep and 
behavior influences, intestinal acid secretion, and glucose regulation (182, 264).  
Evidence has suggested that ghrelin can affect sleep-wake patterns (250) and be a sleep-
promoting factor in humans (283).  Based on these observations, ghrelin may not directly 
augment GH release but instead, be a critical signaling hormone of nutritional and sleep 
status to GH regulation.   Ghrelin appears to be more involved with maintaining energy 
balance through simulating food intake and decreasing fat oxidation.  This may ensure 
that sufficient amounts of energy are available for GH to execute its biological effects 
(106, 254). 
The role of ghrelin in response to exercise is unclear considering the amount of 
contradictory results that reflect increasing, decreasing and unchanged exercise-induced 
ghrelin concentrations (54, 142, 220, 236). It is hypothesized that GHRH, stimulated by 
ghrelin, is required to evoke maximal GH values in humans and that the relationship is 
more pronounced in females.  Additionally, a consecutive ghrelin pulse release-evoked 
GHRH inhibition of SMS outflow to both the ArC and the pituitary gland in males can 
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inhibit the GH response and a single ghrelin pulse will have less effect on GHRH-
induced GH secretion during a GH trough than a pulse (75).  This suggests that GH-
release from the pituitary may be less sensitive to GHRH between GH pulses or that 
other neuroendocrine hormones (i.e. SMS) are inhibiting GHRH at this time.  For 
example, when ghrelin is injected in rats during a GH trough period, GH release is 
markedly attenuated.  This corresponds with the cyclical release of SMS; however, 
Tannenbaum et al. (243) was able to immunonuetralize SMS and show that SMS-
mediated attenuation of GH can be abolished completely.  In humans, the attenuation of 
GH releasing activity was only partial (66).  This means that 1) ghrelin can independently 
stimulate GH release without inhibiting SMS and 2) SMS antagonizes ghrelin’s effect on 
GH release to some degree.   Furthermore, Dimaraki et al. (64) reported that 
hypothalamic GH release does not require declines in endogenous somatostatin 
suggesting that ghrelin can act independent of GHRH and SMS and may play a role in 
the diurnal rhythm of GH.   
Short- and Long-Loop Autofeedback Regulation of GH  
The short-loop feedback loops regulate GH release and are important for 
maintaining homeostasis.  Some of the biological consequences of elevated plasma GH 
that work through a short-loop autofeedback mechanism are through the hypothalamus or 
the pituitary itself.  These include 1) increased hypothalamic SMS which leads to SMS 
neurologically blocking GHRH production and increasing pituitary SMS receptor 
sensitivity, 2) decreased hypothalamic GHRH and decreased GH receptor sensitivity in 
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the pituitary gland, and 3) decreasing hypothalamic and pituitary ghrelin receptor 
sensitivity (83, 276).  
GH’s primary endocrine target is to bind its receptor on the liver.  Here, it 
stimulates the biosynthesis and release of insulin-like growth factor-1 (IGF-1) and to a 
limited extent, insulin-like growth factor-2 (IGF-2) (87, 134).  IGF-1 is a 70-amino acid 
protein that is expressed in a wide range of tissues with most of its synthesis occurring in 
the liver.  The rate at which GH is released from the pituitary can also affect IGF-1 
synthesis and release.  In skeletal muscle and rib growth plates in rats, pulsatile compared 
to continuous GH treatment resulted in a 3-5-fold increase in the levels of IGF-1 mRNA 
and protein expression demonstrating that the pattern of GH release is also an important 
factor in determining its biological effects (122).   However, IGF-1 is known to exert a 
negative long-loop, multilevel feedback effect on GH secretion by acting at the 
hypothalamic and pituitary level.  One pathway of the loop directly inhibits IGF-1’s own 
production by inhibiting pituitary somatotrope cells from producing GH.  The other loop 
alters GHRH and SMS release from the hypothalamus that can subsequently decrease GH 
production and release from the pituitary.  However, this mechanism of the IGF-mediated 
GH suppression may be gender specific.  One study reported that circulating IGF-1 
suppresses plasma GH concentrations by 50-80% regardless of gender (149).  In contrast, 
it has also been reported that IGF-1 suppresses GH secretion exclusively at the 
hypothalamic level because GHRH-induced GH still occurred in the presence of elevated 
plasma IGF-1 in females only.  In males, this was not the case suggesting that other sex 
steroids may also interact with the GH/IGF-1 axis (91).  
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This negative feedback loop can also work in favor of GH production and release 
from the pituitary.  Under normal conditions, a small decrease in IGF-1 is associated with 
a large increase in GH release stemming from the hypothalamic level.  However, this 
must be mediated by SMS and GHRH tone and it is well known that there is a multifactor 
effect on the hypothalamic-pituitary axis.  If reduced IGF-1 autofeedback to the 
hypothalamus fails to increase GH there must be other neuroendocrine factors involved 
(i.e. increased SMS tone and/or decreased GHRH tone) (218).   
The GH/IGF-1 negative feedback loop can be counteracted by exercise suggesting 
that the exercise stimulus is powerful enough to override the inhibitory feedback of GH 
and/or IGF-1 on hypothalamic neurons (129).  Short-term caloric restriction studies have 
demonstrated a GH/IGF-1 axis mechanistic override in the liver as well, as IGF-1 has 
been shown to decrease 50-67% after only 5-14 days of caloric restriction (47, 79).  
These studies have shown large increases in GH without an increase in IGF-1 (199).  The 
likely candidate is a decrease in GH receptor sensitivity at the liver and subsequent 
downregulation of the JAK2 signaling pathway (25). 
It has been demonstrated in sleep deprived rats that the significant decrease in 
plasma IGF-1 concentrations are consistent with the absence of high-amplitude GH 
pulses and overall suppression of GH (73).  In their study, sleep deprived rats with 
reduced IGF-1 levels failed to trigger GH release.  Thus, it appears that sleep deprivation 
results in an altered state of hypothalamic neuroendocrine regulation that may involve the 
IGF-1 long loop feedback mechanism as well.  Unfortunately, exercise was not part of 
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their study methodology and therefore, the ability of exercise to override the 
hypothalamic-pituitary axis was not reported.  
Biological Effects of GH 
In the plasma, most GH is bound to GH-binding proteins and is taken up by 
specific GH receptors on target cells.  GH targets several organs including the heart, 
liver, kidneys, skin, heart, gastrointestinal tract, spleen, bone marrow and skeletal muscle 
(276) and has been linked to the maintenance of lean body mass and exercise capacity 
(293) and decreased cardiovascular disease (156).   In GH deficient individuals, 
exogenous GH supplementation within the normal physiologically range can reduce the 
prevalence of insulin resistance syndrome (48) and improve insulin sensitivity and 
whole-body glucose metabolism (9).  Growth hormone exhibits its functional effects on 
local tissues by increasing lipid metabolism, increasing free fatty acid (FFA) mobilization 
and glycerol concentrations, and inhibiting glycolysis and increasing protein synthesis in 
skeletal muscle (67, 71, 96, 141, 173-174, 214, 278, 304).  As discussed earlier, most of 
these local effects of GH are mediated by its stimulation of IGF-1 biosynthesis through 
regulation of IGF-1 peptide and receptor expression in all major organs, and to a lesser 
extent IGF-2 (264).  
Role of GH in Body Composition 
Major health problems such as obesity, diabetes and heart disease are related to 
body composition.  Increased lean muscle mass can improve metabolic rate and hinder 
disease progression.  The acquisition of lean muscle mass is controlled by a variety of 
hormones, one of which is GH.  In addition to having an effect on lipolysis, exercise-
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induced GH release has also been linked to the inhibition of protein catabolism,  protein 
synthesis in skeletal muscle (34, 81) and tissue remodeling (89, 141). Maintaining the 
correct ratio of protein breakdown to protein synthesis in the body is essential to 
achieving an ideal body composition composed of small amounts of fat mass and large 
amounts of lean body mass.  GH is linked to decreased fat mass and the acquisition of 
lean muscle mass and strength in young adults (41, 117, 278).  Burt et al. (41) examined 
the GH induced changes in body composition in order to clearly define its role on lean 
body mass.  They reported that fat mass decreased and lean body mass increased 
significantly during exogenous GH supplementation of 6 µg/kg/day in GH deficient 
adults vs. a lower dose of 3 µg/kg/day.    
Lean body mass accounts for 80% of the variation in resting energy expenditure 
in healthy adults, with the remaining variation in energy expenditure predicted by skeletal 
muscle blood flow.  There is a significant relationship between GH secretion at rest and 
REE in young adults (28).  Caloric expenditure is directly correlated to resting energy 
expenditure (REE) and since expending more calories generally results in a decrease in 
body weight, it can be hypothesized that GH is linked to improved body composition 
changes.  
Role of GH in Lipolysis 
GH binds to its receptors on adipose tissue and stimulates the mobilization of 
lipids for oxidation through fatty acid and glycerol release while inhibiting triglyceride 
formation and enhancing protein turnover in muscle tissue (59, 71).  The lipolytic actions 
of GH in adipose tissue resemble those of the most potent lipolysis stimulators 
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[catecholamines] (229) and are likely mediated through activation of the JAK2 tyrosine 
kinase complex and subsequent downstream cyclic adenosine monophosphate (cAMP) 
activation leading to the activation of hormone-sensitive lipase (HSL) (10, 302).  The 
synergistic effect of GH and catecholamines on lipolysis was demonstrated by 
enhancement of GH stimulated cAMP production in adipocytes in the presence of 
catecholamines, while in turn, GH sensitizes adipocytes to catecholamine binding (10, 
282).  Studies have shown increased lipolysis in the absence of insulin or glucagon 
secretion further exemplifying the role of GH in lipolysis (258).  GH also has varying 
effects on lipolysis depending on adipose tissue regions; with abdominal regions being 
most prominent (96) and maximum free fatty acid release has been linked to the 120 
minutes following peak nocturnal GH release (217). It is also known that age affects the 
ability of GH to regulate the lipolytic response as younger individuals responded better to 
GH administration than older individuals (258).   
Growth hormone has an effect on lipid oxidation during exercise and several 
hours into recovery.  Pritzlaff et al. (211) reported that post-exercise fat oxidation, peak 
GH, and total GH concentration increased linearly with intensity of exercise.  Subjects 
exercised for 30 minutes at intensities of 25 and 75% of the difference in O2 uptake 
between rest and lactate threshold (LT), LT alone, and at 25 and 75% of the difference 
between O2 uptake at LT and VO2peak.  During exercise recovery, a regression analysis 
revealed fatty acid oxidation increased linearly with intensity as did both peak GH and 
GH AUC.  Thus, GH may be at least partially responsible for utilizing more fat from 
adipose tissue during and following exercise and GH may play a role in post-exercise 
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hypoglycemia.  Enevoldsen et al. (71) examined the role GH plays in post-exercise fat 
oxidation by inhibiting GH release by infusing a somatostatin analogue (octreotide), 
following submaximal aerobic exercise at 50% VO2max.   The somatostatin analogue had 
no effect on lipolysis and subsequent adipose tissue glycerol and FFA concentrations 
during exercise.   However, octreotide infusion inhibited GH release during exercise 
recovery and correlated with inhibited lipolysis after exercise.  Arterial GH concentration 
increased with exercise in the control group only, reaching peak values about 30-45 
minutes into exercise and decreasing steadily after cessation of exercise until baseline 
levels were re-established at 60 minutes post-exercise.   This suggests that the exercise-
induced increase in lipolysis is upregulated by GH in adipose tissue following, but not 
during exercise.  An increase was seen in adipose tissue glycerol and FFA release 
beginning at 60 minutes post-exercise and this time delay for increased FFA oxidation 
was also noted in other studies (67, 96, 100, 173).  Thus, most research supports the 
concept that GH is involved with enhanced fat-oxidation and prevention of post-exercise 
hypoglycemia observed during the post-exercise recovery period. 
Exercise-Induced GH Release 
GH is secreted in a pulsatile fashion with the highest concentrations occurring 
after sleep and exercise.  Although there is large inter-individual variation in exercise-
induced GH release (155), it is reasonable to assume that it is a reproducible measure 
within subjects (235).  An acute bout of exercise lasting as little as 6 sec (234) can 
stimulate a significant GH pulse that typically returns back to baseline within 2 hours.  
However, numerous studies have demonstrated a large augmentation effect of exercise on 
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GH release using a wide variety of exercise protocols and have also demonstrated that the 
alterations in exercise intensity and duration (equating to increases in workload) have 
been shown to increase the exercise-induced GH response in a positive linear fashion (40, 
45, 76, 89, 211-213, 237, 287-288, 296, 293-295).    
Acute Sprint Exercise 
Although there is an intensity component with exercise-induced GH release, it 
does not need to be a supermaximal workload for extended periods of time.  Multiple 
studies have proven shorter bouts of high-intensity exercise elicit an elevated growth 
hormone response (129, 186, 231-236).  Peak GH secretion occurs 40 minutes after the 
cessation of sprint exercise and stays elevated for 90-120 minutes (232-233).  Nevill et al 
(186) and Stokes et al. (234) both demonstrated that a single 30-second sprint could 
augment a significant increase in peak GH concentrations and GH AUC release.  Stokes 
et al. (234) examined the exercise-induced GH response after 6 and 30 seconds of 
maximal cycling exercise using a resistance equivalent to 7.5% of the subject’s body 
mass.  There were no differences between the power outputs of the participants within the 
first 6s of either the 6s or 30s trials.  Serum GH concentrations were elevated after both 
trials, however the magnitude of the elevation after the 30s sprint was greater than the 6s 
sprint.  Serum GH peaked at 40 min post exercise in both trials and remained elevated for 
60 min after the 6s sprint and 90-120 min after the 30s sprint.  The 30s sprint produced 
elevations in GH to 18.5 ± 3.1 µg/l at peak, an increase of 530% from baseline, whereas 
the 6s sprint produced a GH concentration of only 4.0 ± 1.5 µg/l at peak concentration or 
217% above baseline concentration.  This represented a 450% greater maximal GH 
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concentration release after the 30s vs. the 6s exercise trial.  Stokes et al. (233) also 
examined the exercise-induced GH response to maximal sprint cycling at different 
pedaling rates.  Subjects completed two 30s maximal sprints separated by 60 min of 
recovery.   Resistance for the subjects was set at either 7.5% (fast) or 10% (slow) of their 
body weight to elicit different pedaling rates.  There was no difference in peak or mean 
power output between the two trials, but regardless of the randomized order of trials, the 
second sprint had a signficantly lower peak power output regardless of resistance (fast or 
slow).  Peak GH response after the initial fast sprint was more than twice as great as that 
after the initial slow sprint (37.7 ± 6.0 vs. 17.6 ± 3.7 µg/l respectively; p < 0.05) and 
mean GH area under the curve (AUC) during 60 minutes of recovery from sprint 1 was 
also elevated in the fast vs. slow trial (1,697 ± 367 vs. 933 ± 306 µg/l respectively; p = 
0.06).  The results from these two studies suggest that the duration of a maximal sprint 
exercise bout and the subsequent increase in total work has a significant effect on both 
the amplitude and duration of the GH response.  There was no increase in serum GH 
concentration after the second sprint in either trial although the rate of GH clearance did 
slow after the second sprint.  The exact mechanism for the increase in serum GH 
concentration due to faster pedaling rates is not known, but could be related to 1) the 
amount of muscle mass recruited suggesting there is a mechanical mechanism of muscle 
contraction involved in GH secretion, and 2) the result of increased frequency of neural 
firing during the fast trial as there was significant correlation between mean pedal 
revolutions and GH AUC (r = 0.59, p < 0.01 for sprint 1) as well as peak pedal 
revolutions (r = 0.48, p < 0.05 in sprint 1).   
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Short-term high-intensity exercise results in a larger GH secretion than 
submaximal aerobic exercise, which is often followed by an attenuation of GH release 
when multiple bouts of sprint exercise are employed.  Stokes et al. (232) reported an 
attenuation of the GH response after the second successive exercise sprint.  Subjects 
completed a 30s sprint on a cycle ergometer followed by either 60 or 240 minutes of 
passive recovery before attempting another 30s maximal sprint.  Results indicated that 
the GH response did not increase following the second sprint after the 60 minute recovery 
trial.  However, GH concentration was back to baseline by 120 minutes during the 240 
minute trial, and thus the second sprint produced a second increase in GH concentration.  
Notably, the secondary exercise-induced GH release was smaller in magnitude than the 
initial GH response.  Even though the amount of recovery time influenced the amount of 
GH released, similar GH outputs were seen the next day suggesting that there probably is 
an optimal recovery time following sprint exercise to attain maximum exercise-induced 
GH release.  These findings contradict those of Kanaley et al. (129), that reported 
subesequent 30 min aerobic exercise bouts following a similar 60 minute passive 
recovery period both produced significant GH pulses that were equally elevated above 
resting GH values.  One must be careful when interpreting these results as the aerobic 
exercise study recorded much lower GH AUC after exercise than that observed in the 
sprinting study.  Overall, these studies suggest that GH may be regulated by its own 
autofeedback release and there may be an interaction between optimal recovery time and 
total exercise workload.  
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Acute Aerobic and Resistance Exercise 
 A complete review of the aerobic or resistance exericse-induced GH response is 
beyond the scope of the current document, but both are potent stimulators of GH release.  
A brief overview is given here as a comparison for the acute sprint induced changes in 
GH output.  
Sutton and Lazarus (237) first compared exercise to various pharmacological 
stimuli known to increase GH release.  The exercise stimuli included 20 minutes of a 
constant cycling load at 300 (25-33%), 600 (40-66%), and 900 kpm/min (75-90% of 
VO2max).  Physiological stimuli used to induce GH release were arginine, L-DOPA, 
insulin hypoglycemia, and sleep.  The highest GH elevations were obtained following the 
most intense exercise with GH concentrations reaching 35.1 ± 6.3 µg/L after 900 
kpm/min of exercise, similar to the GH concentrations attained with insulin-induced 
hypoglycemia (36.0 ± 5.0 µg/L).  Low intensity exercise was not sufficient to produce 
pronounced elevations in GH leading the investigators to theorize that a minimum 
intensity “threshold” was necessary to produce significant GH elevations in the blood and 
this was confirmed by other groups decades later (76, 212).  Pritzlaff et al. (212) 
examined the impact of exercise intensity on exercise induced GH release.  Constant load 
exercise was performed for 30 minutes at 5 different exercise intensities (2 below, 2 
above and one at LT).  GH release significantly increased prior to LT, and there was a 
direct linear relationship between exercise intensity and the growth hormone response 
across a broad range of exercise intensities.   
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Weltman et al. (289) showed that both intermittent and continuous exercise (3 – 
10-min bouts vs. 1 30-min bout) at constant exercise intensity resulted in significant 
elevations in 24-hour GH AUC compared to the control conditions; yet both methods of 
exercise produced similar 24-hour GH AUC.  Thus, structured physical activity even at a 
low intensity for a short duration (only 10 minutes), whether continuous or intermittent, 
can significantly enhance 24-hour AUC in young adults. Exercise duration also 
influences the extent of GH release in response to acute aerobic exercise.  If exercise 
intensity was held constant, prolonging the exercise duration can augment additional GH 
release (40, 292).  Finally, the frequency of exercise also plays a role in GH release as 
Kanaley et al. (129) demonstrated that repeated bouts of exercise on the same day 
significantly decreased GH release, but they did not measure its effect on total 24-hour 
GH AUC.    
Kraemer et al. (143) demonstrated significant GH release following a heavy 
resistance, high volume routine while others have demonstrated the same using a low 
volume resistance training program (266).  Recently, Thomas et al. (249) reported a 
significant GH release following an acute bout of high-volume, whole-body resistance 
training session.  Therefore, GH release is augmented in normal individuals following a 
variety of resistance training protocols that inlude both low and high volumes of 
workload.     
Regulation of Exercise-Induced GH Release  
The mechanisms behind exercise-induced GH release are thought to be the result 
of neural stimulation, autofeedback, insulin-growth factors, circulating catecholamines, 
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lactate and/or nitric oxide and change in acid base balance (mainly H+ ion accumulation) 
(89, 94).   GH inhibits its own release at the pituitary gland (2008) and hypothalamus 
largely due to an increase in somatostatin or decrease in GHRH release (147).   In 
addition, exercise-induced catecholamines and opiates are linked to the hypothalamic 
release of somatostatin that has an inhibitory effect on GH release (288). 
Following acute exercise, GH increased significantly but was suppressed 2.5 to 4 
hours post-exercise (128).  It is unlikely that this reflects depleted pituitary GH stores 
because repetitive exercise studies have shown exercise to override the negative 
autofeedback loop (mediated by IGF-1) and release GH with as little as one hour between 
exercise bouts (129).  Exercise not only affects total GH release (largely measured as GH 
AUC over a given time interval), but it also affects secretory patterns.  Repeated bouts of 
exercise on the same day significantly increase GH pulse amplitude and mass per burst 
(129).  This is important considering that pulsatile secretion determines more than 85% of 
the daily GH AUC release and that the pulsatile release of GH is more effective at 
producing a biological response than continuous release in certain tissues like bone, 
muscle and liver where GH plays a metabolic role (273).  For example, a large pulsatile 
release of GH compared to a lower continuous GH release is associated with a greater 
IGF-1 concentration (264).  
Most studies have reported that training attenuates resting GH secretion as well as 
the exercise-induced GH response (29, 60, 232, 290); yet some have reported an 
increased GH secretion following exercise training (32, 288).  Because repetitive bouts of 
exercise with short recovery periods already show attenuated GH release, it is difficult to 
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dissociate chronic from acute effects of exercise during training studies because the 
literature seldom states the time lapse following the previous exercise bout.  Therefore, 
the pulsatile release of GH may be affected differently depending on exercise training 
protocols and conflicting research exists in the literature.  However, the attenuated GH 
response following exercise training may be linked to increased tissue sensitivity to GH 
as a result of training that is not likely occurring following acute exercise.  The chronic 
and repetitive presence of GH that continually feeds back to the pituitary and 
hypothalamus across training regimens may reduce the amount of GH release seen in 
response to any given exercise stimulus (i.e. a greater exercise intensity to elicit a greater 
GH response) (300).  Since IGF-1 increased following two weeks of training in one 
study, another possible mechanism may be the enhanced negative feedback of IGF-1 on 
GH release.  This same study also reported increased affinity of GHBPs and GH receptor 
desensitization that further displays the complexity of the hypothalamic-pituitary axis 
(216).  
Most studies report no effect of anaerobic training on resting GH concentrations 
but there is an attenuation of exercise-induced GH release.  Eight weeks of heavy 
resistance training does not affect resting GH concentrations, regardless of gender (143).  
However, they did speculate that different GH variants might adapt and have different 
biological activity following resistance training.  Stokes et al. (231) examined 6 weeks of 
sprint training on GH secretion.  Despite improvements in performance, resting GH 
concentrations were unchanged with training but exercise-induced peak GH and mean 
GH AUC were decreased by 40% and 55% respectively.  However, the type of training 
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and fitness level of the subjects has been shown to affect the exercise-induced GH 
response.  Nevill et al. (186) reported that sprint-trained individuals had a higher 
exercise-induced GH response to high-intensity cycling compared to endurance-trained 
individuals.  This could suggest that the training status of an individual may reflect 
alterations in the sensitivity of the feedback mechanisms regulating the hypothalamic-
pituitary axis allowing for greater exercise-induced GH responsiveness; however, a more 
likely explanation would be greater total exercise workload attained by the sprint-trained 
individuals.     
Effects of Body Composition on Exercise-Induced GH Release 
Obesity has long been known to have a profound effect on GH secretion at rest 
and during exercise (99).  Similar to normal subjects, obese subjects see alterations in 
exercise-induced GH secretion patterns during exercise and training; however, there is a 
discrepancy in what GH secretory parameters are altered.  Kanaley et al. (127) reported 
an attenuated exercise-induced response in obese women and attributed it to a decrease in 
GH mass secreted per burst whereas Veldhuis et al. (275) reported that decreased GH 
secretion in obese individuals was attributed to a decrease in pulsatile GH release and 
shorter GH half-life.  In another study, both intermittent and continuous exercise at a 
constant intensity resulted in significant elevations in 24-hour AUC, but it was attenuated 
in obese subjects.  However, the attenuated 24-hour AUC was related to a decrease in 
basal and pulsatile secretion since GH half-life was similar for all subjects regardless of 
obesity status, signifying that GH clearance was not affected (289).  Regardless of 
inconclusive results on exercise-induced GH secretory parameters, the more important 
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conclusion is what happens to the downstream biological activity of GH once released.  
Exercise protocols that cause increased activation of GH-mediated IGF-1 or lipolysis 
would be of great benefit in the obese population.    
GH release is also attenuated in obese individuals using high-volume, whole-body 
resistance training protocols (249).   One training study that used obese subjects reported 
no training effect on GH release (127), whereas non-obese training studies have reported 
conflicting results using various modes, and intensities of exercise (143, 186, 231, 285, 
287-288, 290). 
24-Hour Growth Hormone Release 
Physiological variations in 24-hour GH concentrations and secretory patterns 
have been well reported.  Age, body composition, physical fitness level and gender are all 
factors that influence 24-hour GH release independently and concomitantly (46, 112, 152, 
156, 204, 219, 262, 272, 275, 286-287, 289).  
Effects of Body Composition on 24-Hour GH Release 
Overall, obesity attenuates 24-hour GH concentration.  High BMI, when 
associated with excess body fat, may directly inhibit GH release by increasing unbound 
IGF-1 (102) free fatty acid concentrations (46) or increasing somatostatin (58), all 
leading to a negative feedback loop on GH release from the hypothalamus.  Since GH 
levels are blunted in obese individuals many of the beneficial effects of GH are 
attenuated in the obese population, regardless of gender or age (124, 198, 219, 289).  GH 
supplementation in adults with a GH deficiency has been correlated with decreased total 
fat mass and an attenuation of lean muscle mass loss (65, 256).  In addition, since blunted 
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24-hour GH concentration in obese individuals are reversed following diet-induced 
weight loss, GH release must be involved (either directly or indirectly), in regulating the 
pathways associated with determining body composition (i.e. lipolysis).  
Decreased basal and altered pulsatile GH secretion dynamics in obese individuals 
constitute the attenuated 24-hour GH AUC (123-124, 272, 289).  Iranmanesh et al. (123) 
reported that BMI had a significant negative linear correlation with GH half-life and 
secretory burst amplitude and.  Veldhuis et al. (272) confirmed the negative relationship 
between BMI and body fat percentage to GH secretory burst mass.  Additionally, peak 
24-hour GH concentration can be reduced by 1.02 µg/L for each 1 cm increase in waist 
circumference (155).  However, there are varying opinions on which anthropometric 
measure or body composition variable (BMI, body fat percentage, intra-abdominal 
visceral fat, waist-to-hip ratio) best predicts 24-hour GH concentration.  Results from 
previous studies suggest that body composition (percentage body fat or 
compartmentalized fat distribution), is a better predictor of total GH concentration than 
BMI alone.  Vahl et al. (258) reported mean serum 24-hour GH concentration correlated 
inversely with intra-abdominal adiposity and waist-to-hip ratio and were a stronger 
predictor of 24-hour GH concentration compared to age and sex.  Clasey et al. (46) also 
concluded that abdominal visceral fat was a stronger predictor of the pulsatility pattern of 
GH over a 24-hour period compared to BMI, regardless of age or gender.  Weltman et al. 
(286) reported that elevated intra-abdominal visceral fat resulted in a 40-50% reduction in 
24-hour GH concentration.  They used both percent body fat and BMI in their regression 
model, they concluded that percentage body fat, not BMI, was related to 24-hour GH 
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concentration in young adults.  However, in a recent study involving 100 healthy adults, 
24-hour GH concentration was simultaneously determined by BMI along with gender and 
IGF-1, while peak GH (single daily maximum) concentration was significantly 
influenced by BMI and IGF-1 in both males and females (275).  However, the strength of 
the BMI results should be interpreted with caution, as they did not use percent body fat in 
the regression analysis along with BMI.  
Combined Effects of Body Composition and Gender on 24-Hour GH Release 
Weltman et al. (286) reported that age and percent body fat, but not BMI, is 2.6 
times more related to 24-hour GH concentration in males compared to females.  
Furthermore, Veldhuis et al. (275) reported that females have a more unpredictable 
pattern of GH release (higher ApEn scores), thus males are more likely to have a negative 
linear relationship to body composition because the lower statistical variance of the 
regression analysis for GH concentration and body composition creates a stronger 
relationship between the two variables compared to females.   
Several studies have reported that basal and exercise-induced GH concentrations 
are inversely related to BMI (46, 124, 169).  However, one must be cautious when 
interpreting BMI used in a regression analysis to predict GH concentration because of the 
effect of gender and age on the type of relationship (linear vs. non-linear), especially at 
BMI ranges less than 27 kg/m2 (2, 84, 125, 164).  BMI does not distinguish between lean 
and fat mass and phenotypic differences in body composition are known to be gender-
mediated (299).  In general, females accumulate more subcutaneous fat than visceral fat 
compared to males and males have more lean muscle mass in their arms while females 
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tend to have more fat mass accumulation in the lower body (267, 299).  GH is known to 
be largely involved in the pathway that regulates lipolysis (184, 211, 304).  Thus, 24-hour 
GH concentration may be influenced by gender differences in subcutaneous vs. intra-
abdominal fat reserves and/or the presence of hormonal mediators associated with 
differences in body composition between genders.  For example, the relationships 
between GH-related somatotrophic hormones that mediate the effects of GH, such as 
insulin-like growth factor (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-
3) and leptin, with lean soft tissue mass is different between males and females (198).  
This helps to explain the differences in GH pulsatile profiles between genders over a 24-
hour period.  
Gender-mediated phenotypic differences with higher body fat percentages may 
help to explain why the relationship between BMI and 24-hour GH release is stronger in 
females.  This stronger relationship at higher BMI levels may have little to do with actual 
BMI per se, but may occur due to gender-mediated concomitant changes in other cardio-
metabolic factors known to influence GH release (i.e. intra-abdominal visceral fat, 
diabetes, age, lower fitness levels, sex-steroid concentrations, etc.).   
Effect of Age on 24-Hour GH Release 
Iranmanesh et al. (123) reported age as having a negative linear effect on GH 
secretory burst frequency, half-life and GH secretory rate but not GH burst amplitude or 
mass; whereas BMI had a significantly negative linear correlation with GH half-life and 
secretory burst amplitude.  Together, age and BMI accounted for 60% of the variability in 
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24-hour GH production rates where each unit increase in BMI, at any given age, reduced 
the 24-hour secretion rate by 6%.   
Effect of Fitness Level on 24-Hour GH Release 
Weltman et al. (286) reported that fitness levels (as assessed by VO2peak) were 
significantly correlated with 24-hour GH concentration in males, but not females.  Their 
regression analysis revealed the linear relationship of VO2peak to total GH concentration 
was 1.9 times greater in males compared to females for every unit of standard deviation 
change in VO2peak.   However, these gender differences must be interpreted with caution 
because males had a significantly greater VO2peak.   Vahl et al. (258) reported that 
VO2max, similar to VO2peak, was more important than sex and age in predicting 24-hour 
GH concentration.  Furthermore, Weltman et al. (289) reported individuals with higher 
fitness levels (assessed by VO2peak) secreted greater amounts of GH over a 24-hour period 
and this relationship was linear.  Therefore, those with higher levels of physical fitness 
(VO2peak) had higher levels of resting 24-hour GH concentration and physical fitness 
appears to be just as important as body composition, sex and age in predicting 24-hour 
GH concentration.    
The magnitude of difference in muscular strength between genders is smaller 
when the amount of fat-free mass is considered instead of total body mass (263).   
Phenotypic differences that exist between the genders can affect the pathways that 
regulate physical fitness and subsequent exercise capacity.  Thus, 24-hour GH 
concentration may be perpetuated through factors and pathways regulating the ability to 
perform acute exercise (lean muscle mass, substrate utilization, etc.).  This suggests that 
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both fitness and exercise capacity should be concomitantly examined when determining 
24-hour GH concentration.   
Effect of Caloric Restriction on GH Release 
Energy (caloric) deficit and high/low-macronutrient diets induce changes in 
exercise-induced GH secretion.  High-caloric diets have been reported to influence GH 
secretion without a subsequent change in body composition.  Comford et al. (49) reported 
that 70 kcal/kg fat free mass or 75% more calories than a normal weight-maintaining diet 
can significantly reduce GH secretion after only 3 days.  The reduction in GH secretion 
occurred without a parallel reduction in body weight or other factors that regulate GH 
production such as plasma IGF-1, cortisol, free fatty acid concentration or glucose (301). 
Likely, the reduction in GH observed during high-caloric diets is related to elevated 
insulin levels as previously reported by Yamashita & Melmed (301).  On the contrary, 
low-caloric diets have the reciprocal effect on GH secretion. Koutkia et al. (140) reported 
that 4 days of a low-caloric diet increased basal GH and peak GH concentrations in 
healthy women and this relationship was reciprocal to ghrelin.  Ghrelin, which is known 
to increase during caloric restriction to stimulate appetite, was shown to decrease in the 
presence of increased GH during a low-caloric diet and thus, GH exhibits a feedback 
inhibition on ghrelin secretion.   
Longer and more severe periods of caloric restriction result in changes in total GH 
production and secretory dynamics.   After 36 hours of fasting, Maccario et al. (154) 
reported an 1140% increase in GH production.   GH mean burst mass was reported to 
increase 200% and GH production rate increased 400-500% in older men after a 48-hour 
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fast (103).   Longer periods of fasting lasting from 3-5 days have resulted in very large 
increases in mean GH concentrations and peak amplitude (43, 114).   
Circadian Rhythm and Sleep Deprivation  
Circadian Rhythm  
Humans have an endogenous timing system that synchronizes behavior (sleep-
wake cycles) with the solar day (circadian rhythm).  The circadian rhythm, also referred 
to as the circadian clock, is generated by the suprachiasmatic nucleus (SCN); however, 
peripheral tissues such as the heart and liver may also have circadian clocks that respond 
to endogenous signals.  The SCN is a bilateral structure that contains ~50,000 neurons 
and is located in the anterior hypothalamus (303).  The rhythm re-generates itself, on 
average, every 24 hours and creates a biological night and day that alternate in a cyclic 
fashion (51, 53). In order for the endogenous timing system to synchronize with its 
environment (sleep-wake cycle), external input is needed to cue the phase shift of the 
cycle.  Therefore, the circadian rhythm is concomitantly regulated by changes in non-
photic and photic factors such as oscillating hormones, sleep-wake cycle, exercise and 
food intake.  The greatest circadian synchronizer is light exposure.  Light, known as a 
photic stimulator, is detected by photoreceptors in the eye and processed by specialized 
ganglion cells that are distributed throughout the retina. The signal travels along the 
retino-hypothalamic tract to the SCN in the hypothalamus where it is distributed to 
various glands and tissues to modify hormonal secretions (52, 69).   In the absence of 
light exposure, circadian rhythms lack their usual 24-hour clock and thus, light exerts a 
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powerful resetting effect on circadian rhythm.   This also resets the neuroendocrine 
rhythm leading to the oscillations witnessed over a 24-hour period with certain hormones.    
 It is possible to adjust the circadian clock via laboratory protocols or jet lag and 
the speed of adjustment tends to be 1-2 hour per day (69, 291).  The mechanism behind 
the adjustment is exposure to light hours before the regular circadian nadir, or in other 
words, light exposure during the nighttime period when there is not expected to be any 
exposure to light (51, 53).   Obviously, light exposure during the biological daytime has 
no effect on circadian shift.  In mammals, light exposure before the period of darkness 
ends will delay the circadian rhythm while light exposure after the period of darkness 
begins will advance the rhythm.  To extrapolate this hypothesis to humans is difficult 
because humans are normally asleep with their eyes closed during the biological 
nighttime.  Thus, exposing humans to light during the biological night could possibly 
shift the circadian rhythm and alter hormonal release; however, the concomitant effect of 
keeping subjects awake during normal sleeping hours makes hormonal measurements 
complicated to interpret due to the interaction with the alteration of the sleep-wake cycle.  
A good theoretical example of this phase adjustment is transmeridian travel.  As humans 
travel westward they are exposed to light for later periods in their biological clock and 
thus, their clock is delayed.  As such, humans typically have more difficulty traveling 
eastward as light exposure is diminished and their circadian clocks are advanced (298).  
 Research on circadian shifts in the absence of light exposure suggests that non-
photic cues can drive circadian rhythm as well, at least to a minor effect.  The most 
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significant non-photic signals include melatonin, feeding and temperature (176).  
Additionally, vigorous exercise may act as a circadian synchronizer (15, 42).  
Sleep-Wake Cycle and Sleep Deprivation 
Sleep is characterized by a reduction in motor output and the absence of 
consciousness.  It is associated with changes in posture, temperature and light exposure.  
Humans spend approximately one-third of their lives sleeping (176).  Sleep is a 
multifaceted process that consists of a dynamic alteration between REM and NREM 
stages.  NREM sleep is further classified by intensity into four stages.  Stages 3 and 4 are 
considered the deepest form of sleep and are considered SWS.  Recently, the American 
Academy of Sleep Medicine has re-categorized the NREM sleep stages into N1, N2, and 
N3.  SWS is dominant during N1.  Sleep intensifies during N2 and becomes REM sleep 
in N3 (118).    
Sleep is critical for the maintenance of health and some of the clinical states 
associated with sleep deprivation include cardiopulmonary, metabolic and 
cerebrovascular disease, thrombotic disease, arthritis, mood disorders and shortened life 
span (7, 70, 144). Evidence of the effect of sleep deprivation on altered hormone 
secretion suggests the hypothalamus as the primary locus affected and secondarily, the 
pituitary gland.  Animal and human studies have shown profound effects on circulating 
hormones relating to chronic sleep deprivation (36, 39, 73, 202, 221, 240, 260-261, 297).  
Sleep Deprivation in Society 
Today’s societal demands of 24-hour services (healthcare, industry and 
transportation) can wreak havoc on the physiology of the normal circadian clock.  
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Athletes that awake early to travel or compete in the evening have difficulties 
maintaining a normal sleep-wake cycle as well.  Shift work is associated with several 
health disorders (cardiovascular disease, gastrointestinal complications) as well as sleep 
disorders, increased risk for accidents and fatigue (5).  These diseases, disorders and 
complications likely occur as a result of uncoupling the normal sleep-wake cycle from 
the innate circadian rhythm.  When this uncoupling occurs, the circadian clock may be 
promoting sleep and release of hormones while a person is attempting to stay awake and 
alert.  In contrast, individuals who are trying to sleep during the day may have difficulty 
staying asleep because their circadian clock is promoting alertness.  Alertness 
immediately starts to decrease shortly after awakening and continues until sleep is 
achieved (80).  Shift workers are subjected to a de-synchronization of the circadian 
rhythm and altered sleep patterns resulting in altered hormonal profiles.  They also report 
more sleep disturbances and have more work related accidents than day workers (8).  
Numerous studies have documented that despite several years of working a 
nightshift schedule, the body’s circadian rhythm never completely synchronizes with the 
innate sleep-wake schedule of night shift work.  This is likely because the circadian 
adjustment of nightshift workers is counteracted by light exposure during the early 
morning when they are attempting sleep.  Thus, these workers are in an internal 
environment of constant hormonal de-synchronization (228, 253).  
The schematic of sleep habits in night shift workers is much different than 
habitual day shift workers.  The night sleep preceding the ensuing first night shift is 
unusually long (> 8 hours) and is often associated with afternoon napping before the first 
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night shift (136).  Following night shift work, sleep ensues within 1 hour and is reduced 
by 2-4 hours.  Most of the sleep loss results in REM sleep reduction with no reduction in 
SWS (6).  Afternoon naps are common following a night shift and it takes on average two 
night sleep periods before normal sleepiness levels have been achieved again (8).  
Circadian Rhythm and Sleep Deprivation Research Protocols 
Hormonal levels fluctuate throughout a 24-hour period and are controlled by a 
synchronization of the circadian rhythm and sleep patterns.  As sleep progresses, the 
circadian clock is also changing.  This results in a crossover effect of circadian rhythm 
and sleep on neuroendocrine function.  As previously explained, light exposure has the 
largest influence on circadian rhythm.  However, altered sleep patterns can have a non-
photic effect on circadian rhythm.  Therefore, sleep and circadian rhythm work 
synergistically to affect hormonal output.  This makes it difficult to distinguish the effects 
of sleep vs. circadian rhythm alternation on hormonal output when subjects are allowed 
to sleep during the biological nighttime hours.  By using the “constant routine” method, 
modified by Czielser et al. (52), one can dissociate the circadian rhythm and the sleep-
wake cycle.  In this protocol, subjects become sleep deprived by remaining awake for 
long periods of time in a semi-recumbent position in dim, indoor light, receiving frequent 
small meals throughout.  Although the constant routine method is usually used for several 
days, the first 24 hours of the routine is often modified by investigators to differentiate 
nocturnal events generated by the circadian rhythm from those elicited by sleep.  Thus, 
these protocols are often termed “sleep deprivation protocols.”  
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Circadian and Sleep Deprivation Effects on Exercise-Induced GH  
The endogenous circadian effect on the daily rhythm of GH is more difficult to 
distinguish due to GH being tightly correlated to sleep.  The 24-hour profile of GH is 
known to be sleep-dependent but several studies have manipulated sleep-wake cycles to 
attempt to determine the independent effects of circadian rhythm on GH.  These studies 
have reported minimal effects of circadian rhythm on the GH secretory profile (92, 166, 
260-261). Therefore, manipulation of sleep cycles is a better target than circadian rhythm 
in evaluating changes in the body’s natural rhythm of GH secretion.   
Due to the pulsatile release pattern of GH, multiple peaks of various 
concentrations are observed over a 24-hour period.  Within a normal episode of sleep 
during those 24-hours, the major secretory GH pulse occurs just after sleep onset.  There 
are typically several GH pulses averaging every couple of hours.  GH levels increase in 
the late evening shortly before the normal sleep cycle begins in humans and continues to 
rise during the first 4 hours of sleep.   Most GH release occurs during NREM sleep within 
the SWS phase  (202, 221, 240, 260-261) with little GH secreted during REM sleep 
(115).    
Rat Studies on the Effect of Sleep Deprivation on GH 
GH release is significantly reduced and high amplitude GH bursts are completely 
abolished in rats after 1 week of sleep deprivation (73).  In addition IGF-1, prolactin and 
leptin were all suppressed and IGF-1 mimicked the pattern of the abolished GH release.  
In this case, sleep deprivation may have disrupted the normal feedback loops associated 
with GH release.  The sustained decrease in GH release was associated with weight loss 
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and increased food consumption.  On an acute scale, Kimura & Tsai (135) has shown that 
GH pulses in rats are abolished during sleep deprivations of as little as 3 hours.   
Human Studies on the Effect of Sleep Deprivation on GH 
Shifting or reversing the sleep-wake cycle has a profound effect on GH secretion.  
If SWS is deprived, GH release is attenuated or delayed until sleep onset occurs (131).  
When normal sleep is interrupted, there is a second GH pulse upon sleep resumption (26).  
However, even if sleep does not occur within a reasonable time frame (sleep-shift 
protocol) the total amount of GH as well as its pulse secretion parameters is similar to 
habitual sleep patterns (260-261).  When sleep resumes following a time shift episode as 
seen in experimental (sleep deprivation) or environmental (jet lag) situations, GH release 
is markedly increased compared to baseline.  This is due to an increased GH pulse 
amplitude rather than pulse frequency (205, 259, 297).  Usually, GH pulse magnitude is 
determined by sleep onset and SWS; however, when sleep is shifted, REM sleep is more 
involved in determining GH secretion magnitude (171).  This has been shown in sleep-
shift protocols where GH amplitude is significantly reduced even when comparable 
amount of SWS is obtained during daytime hours following a night of sleep deprivation 
(130).  In these scenarios, biological nighttime GH secretion is no longer considered the 
primary mathematical component of total GH release.   
Acute sleep deprivation of 24-36 hours blunts GH secretory amplitude (36, 39).  
Brun et al. (39) showed that compared to a control session, GH concentrations were 
dramatically reduced during a 36-hour sleep-deprived session with the most noticeable 
change being a decrease in the magnitude of the major nocturnal GH peak (5.5 ± 3.4 ug/l 
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vs. 28.2 ± 17.9 ug/l, for sleep deprivation and control, respectively).  Peak nocturnal GH 
secretory bursts were observed in the subjects between 23:00 and 2:30 h during the 
control session.  During the sleep-deprived session, the peak amplitude and total GH 
AUC were dramatically reduced although the number of total GH peaks was not different 
between control and sleep-deprived sessions over a 24-hour period.  Therefore, the total 
GH AUC reduction was a reflection of the reduced magnitude of nocturnal GH secretory 
bursts. Several studies have shown that upon sleep recovery from deprivation, GH 
amplitude levels return to normal quickly (39, 261).  Wiebel et al. (297) studied 11 night 
workers during their usual sleep-wake cycle and compared them to two equal groups of 
normal night sleepers with and without an 8-hour sleep delay.  Total 24-hour GH 
concentration did not differ between groups.  Those shift workers (night sleepers) who 
slept during the day and worked during the night had an increased GH secretion due to 
increased pulse frequency during the first half of sleep compared to night workers.  
Effect of Sleep Deprivation on Exercise-Induced GH Release 
Few studies have examined the effects of high-intensity, short-term exercise on 
GH release following acute (>24-hour) sleep deprivation.  Abedelmalek et al. (1) reported 
that growth hormone was increased following partial sleep deprivation using repeated 
brief sprint exercises similar to the current study.  In Abedelmalek et al. (1), thirty 
healthy, college-aged athletes exercised at 0800h after only being allowed to sleep from 
2230 to 0300h.  During each of their exercise sessions, subjects completed 4 x 250-m 
runs on a treadmill at a constant intensity of 80% of an individualized maximal speed 
with 3-min recovery intervals.  In contrast, Mougin et al. (178) reported that partial sleep 
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deprivation did not affect exercise-induced GH release.   However, in this study, subjects 
were awoken as soon as they were about to enter REM sleep.  They were kept awake by 
pursuing sedentary activities in bed for three hours before being allowed back to sleep 
until 0700h and remained sedentary until their exercise session at 0200h.  Typically, most 
GH release occurs during this NREM sleep phase constituting SWS that occurs within 
these first 4 hours (131, 202, 221, 240, 260-261) with little GH secreted during 
subsequent REM sleep (115).  Thus, subjects in the Mougin et al study (178) were not 
sleep deprived during the NREM phase when most nocturnal GH release occurs and this 
is likely the reason why exercise-induced GH release was similar in both admissions.  
This is in agreement with a much earlier study by Karacan et al. (130), who reported 
lower GH release during sleep deprivation in which subjects were not allowed to enter 
SWS. 
Effect of Sleep Deprivation on Exercise Performance 
Sleep deprivation studies have reported increased blood pressure and heart rate at 
rest  (22, 165, 305).  Fewer studies have reported that sleep deprivation can alter 
physiological variables including oxygen consumption, heart rate and ventilation during 
submaximal and maximal exercise (179, 207) although studies noted that sleep 
deprivation of 24 to 72 hours does not affect cardiovascular or respiratory variables 
during varying exercise intensities (93, 107, 158).  However, fatigue and rating of 
perceived exertion (RPE) during exercise following sleep deprivation have been reported 
to increase (265).  Martin et al. (159) reported that 36-hours of sleep deprivation only 
altered psychological changes (i.e. mood) during submaximal exercise while heart rate, 
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oxygen uptake and ventilation remained unchanged.  However, only light treadmill 
walking was completed by their subjects.  Although the major consensus is that sleep 
deprivation of 24 to 30 hr does not affect cardiorespiratory response during submaximal 
exercise, exercise to exhaustion has reported conflicting results (93, 107, 158,  247).  
Many of these exhaustive exercise protocols are incremental and progressive in nature 
and thus, subjected to the confounding influences of both physical and mental fatigue.  
However, sleep deprivation appears to have less influence on anaerobic exercise.  Hill et 
al. (107) and Vardar et al. (268) both reported that a single 30 s Wingate anaerobic test 
following complete sleep deprivation of 24 hr does not alter anaerobic performance 
parameters such as peak power, mean power and fatigue.  
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Abstract 
 The effect of complete sleep deprivation on exercise performance and cognitive 
function was examined.  Ten male subjects (20.6 ± 1.4 years) were screened for normal 
sleeping patterns before arriving to the first of two randomized 24-hour laboratory 
sessions.  Subjects completed a brief, high-intensity exercise bout following either a night 
of adequate sleep (SLEEP) or complete (24-hr) sleep deprivation (SLD).  The exercise 
bout consisted of four maximal 30-s Wingate anaerobic tests on a cycle ergometer against 
an electronically applied resistance equivalent to 7.5% of their body weight (kg).  Each 
sprint was followed by four minutes of active recovery.  Oxygen consumption (VO2), 
metablic equivalent (METS), expired carbon dioxide (VCO2), ventilation (VE), 
respiratory exchange ratio (RER), respiratory rate (RR), tidal volume (VT), peak VO2 and 
peak METS were collected using open circuit spirometery and telemetry for 30 minutes 
pre-exercise and throughout the exercise session.  Blood lactate concentrations were 
measured at rest prior to and immediately after exercise.  Subjects also performed a 
psychomotor vigilance task (PVT) to measure sensory sensitivity as well as the Paced 
Auditory Serial Addition Test (PASAT) to measure cognitive processing ability.  These 
cognitive function tests were taken four times during each 24-hr session (0800h, 2000h, 
0600h and 0720h) with the latter two taken immediately pre- and post-exercise the 
morning after the night each subject spent in the laboratory.  At rest, HR was 
significantly depressed (p < 0.05) and RR was significantly elevated (p < 0.05) during the 
SLD session.  During exercise, peak HR attained during the SLD session was 
significantly depressed (p < 0.05).  Although peak power obtained during the 1st sprint 
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exercise (p < 0.01) was greater during the SLEEP session, overall mean anaerobic 
performance was similar between sessions.   Lactate was significantly greater following 
exercise within each session (p < 0.01), but was similar between sessions (p = 0.510).   
Polynomial contrasts indicated that there was a significant linear trend (p < 0.05) 
reflecting the slower reaction time for the 4th PVT test.  A Wilcoxon signed-rank test 
confirmed this interaction effect between test order and session by revealing that the 
subject’s reaction time was slower in the post-exercise (4th) PVT of the SLD vs. SLEEP 
session (326 ± 37 vs. 298 ± 21 msec, p < 0.01, respectively).  Our results indicated that 
acute sleep deprivation had minimal effects on exercise performance.  Aside from heart 
rate and respiration, sleep deprivation had no effect on VO2, METS, VCO2, VE, RER, 
RR, VT, peak VO2 or peak METS during rest or exercise. Heart rate was depressed 
following sleep deprivation and remained depressed at peak exercise.  Respiratory rate 
was significantly elevated during rest following sleep deprivation, but differences were 
abolished at the onset of exercise.  Finally, sleep deprivation had no effect on cognition at 
rest, but did have an interaction with exercise during certain task-specific cognitive 
functions of psychomotor performance.  
Keywords 
sprint exercise • sleep loss  • psychomotor • anaerobic • sensory 
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Introduction 
Sleep is an integral component of mental and physical performance.  Although the 
function and mechanistic underpinnings of sleep are not entirely understood, it appears to 
be critical for the maintenance of health and the restoration of central nervous system 
function.  Additionally, many pathological conditions are associated with sleep 
deprivation, including cardiopulmonary, metabolic and cerebrovascular disease, 
thrombotic disease, arthritis, mood disorders and shortened life span (7, 70, 144).  
Occupational, athletic and academic requirements all challenge modern day sleep 
management.  Those undergoing some form of sleep deprivation such as doctors, nurses, 
shift workers and military personnel, provide many of our important societal services.  
Additionally, athletes and coaches believe that sleep is essential for peak physical 
performance in the same manner that students in academia believe that sleep is essential 
for peak mental performance.  There are many situations where sleep is disturbed prior to 
an athletic event including travel, changes in time zones and anxiety.  As a result, 
student-athletes in higher-education may be forced to accommodate their study schedule 
for athletic events, resulting in altered sleep habits and/or sleep loss in order to study for 
exams.  In these situations, the question arises as to what particular forms of exercise 
and/or cognition are affected by sleep deprivation.    
Exercise is known to provide many physiologically and psychological benefits.  
Literature on the effect of complete sleep deprivation (greater than 24 hr) on exercise 
performance and the cardiorespiratory response to exercise is equivocal, likely due to the 
use of varying exercise protocols and experimental designs (22, 165, 179, 207, 247, 305).  
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Although the major consensus is that sleep deprivation of 24 to 30 hr does not affect 
cardiorespiratory response during submaximal exercise, exercise to exhaustion has 
reported conflicting results (93, 107, 158, 247).  Many of these exhaustive exercise 
protocols are incremental and progressive in nature and thus, subjected to the 
confounding influences of both physical and mental fatigue.  However, sleep deprivation 
appears to have less influence on anaerobic exercise.  Hill et al. (107) and Vardar et al. 
(268) both reported that a single 30 s Wingate anaerobic test following complete sleep 
deprivation of 24 hr did not alter anaerobic performance parameters such as peak power, 
mean power and fatigue.   
In addition to the effect of sleep deprivation on exercise performance, it can also 
have detrimental effects on cognition as indicated by impairment in psychomotor sensory 
sensitivity and cognitive processing capacity (14, 57, 146, 210).  These affects are 
highlighted by cognitive slowing, memory impairment, decreased vigilance, and 
decreased response capability (108).  Very little research has approached the idea of 
using exercise as a moderator of the detrimental effects of sleep deprivation on cognitive 
function.  It is believed that exercise can increase the speed of motor processes and 
hyper-activate the link between external arousal and neural activation leading to 
improvements in sensory sensitivity and cognitive processing during sleep deprivation 
(161, 247).  This could be partially explained by exercise-induced changes in heart rate, 
catecholamines and monoamines that can improve brain activity leading to the 
enhancement of deciphering sensory information (57). However, there may be a 
threshold and a time course of adaptation during exercise for beneficial cognitive effects 
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to occur.  A Critical Flicker Fusion (CFF) task is a psychomotor test that requires a 
subject to identify when a flickering light becomes fused and is very similar to the 
Psychomotor Vigilance Task (PVT).  Using the CFF task during steady-state aerobic 
exercise, Davranche & Audiffren (57) did not see improvements in scores until exercise 
intensity reached 50% VO2max.  Thus, it appears there is an intensity threshold of exercise 
for subsequent improvements in sensory sensitivity.  The same is likely true for exercise 
recovery.  Researchers have reported that the effects of exercise on reaction time decrease 
very quickly after exercise cessation (14).  However, the rate of decrease in sensory 
sensitivity during exercise recovery appears to be driven by the intensity of exercise, as 
studies that utilized aerobic exercise to exhaustion protocols reported a more gradual 
decline during post-exercise recovery (210).  
Although several studies have also examined the consequences of submaximal 
exercise and exercising to exhaustion following complete sleep deprivation, few studies 
have examined the effects of complete sleep deprivation on anaerobic exercise 
performance and cardiorespiratory response.  Several studies have reported that sleep loss 
of 12 – 64 hr does not affect anaerobic performance (107, 177, 227, 238, 241, 268); 
however, most of their exercise protocols included a single Wingate anaerobic test or a 
similar volume inferior to the volume of anaerobic workload in the current study and 
definitely not in line with the volume required for most exercise tasks.  The Wingate test 
provides reliable measures of anaerobic exercise performance, blood lactate accumulation 
and exercise-induced peak heart rate (284).  To our knowledge, no one has examined the 
interaction effects of strenuous exercise using successive Wingate anaerobic tests and 
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sleep deprivation on exercise performance, cardiorespiratory response and cognitive 
function. Therefore, the purpose of this study was to investigate anaerobic performance 
and cardiorespiratory response following repetitive high-intensity, short-term anaerobic 
exercise during sleep deprivation.  Secondly, we examined the effect of high-intensity 
exercise during sleep deprivation on subsequent cognitive function.   We hypothesized 
that anaerobic performance during high-volume, high-intensity exercise will be 
attenuated during complete sleep deprivation, but the cardiorespiratory response will 
remain unaltered.  Furthermore, we hypothesized that cognitive function will be 
detrimentally affected by sleep deprivation, but high-intensity exercise will 
counterbalance the effect of sleep deprivation.  
Methods 
Subject Characteristics 
Ten male subjects (9 Caucasian, 1 African-American and 1 Hispanic), ages 18 – 
22 yr (20.6 ± 1.4 yr) with an average body mass index of 26.6 ± 2.5 kg/m2, and body fat 
percentage of 20.9 ± 6.8 %, completed the study.  On average, subjects reported 
participating in high-intensity activity 1 day per week and spent 4 – 6 hours per week 
participating in recreational physical activity and reported minimal occupational physical 
work.  All subjects provided written informed consent in accordance with the institutional 
review board at the University of North Carolina at Greensboro and Winston-Salem State 
University.  All subjects underwent a strict preliminary screening session prior to 
inclusion.  Subjects were excluded if they: 1) had a body fat percentage >30%, 2) 
reported a history of hematological, renal, hepatic, metabolic or thyroid dysfunction, 3) 
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were currently on a caloric restriction program (diet) or taking any medications that 
promoted weight loss, 4) currently smoked or had quit smoking within the previous three 
months, 5) had documented sleep disturbances or irregular sleeping patterns such as night 
shift work or recreational habits, 6) had completed transmeridian travel within the last 
month, or 7) participated in greater than 10 hours of recreational activities (swimming, 
basketball, jogging, cycling etc.) per week or were involved in any type of sprint training 
within the last 6 months.  Self-reported sleep logs were kept for seven days prior to both 
24-hr laboratory sessions and were used to screen for normal sleep patterns.  Epworth 
Sleepiness scales were used to screen for baseline excessive subjective sleepiness and/or 
irregular sleeping habits (126).  Individuals who met the inclusion criteria completed a 
brief familiarization session on an electronically-braked cycle ergometer (Lode Excalibur 
Sport, Lode BV, Gronignen, The Netherlands).  Equipment used to collect metabolic 
measures using standard open circuit spirometry (TrueOne® metabolic measurement 
system from ParvoMedics [(Sandy, UT)] during exercise was fitted during this 
familiarization session, but no gases were collected.   
Experimental Design  
Subjects completed one baseline 24-hour laboratory session where their acute 
exercise response was measured following a night of sufficient rest compared to the 
identical exercise-induced response following a separate 24-hour continuous sleep 
deprivation session.  Subjects were instructed to refrain from exercise the 48 hours prior 
to their randomized laboratory session.  In order to control for order effects, a 
counterbalanced design was used in which half the subjects performed the sleep 
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deprivation session (SLD) first and the other half performed the control sleep session 
(SLEEP) first (Figure 3.1).  Testing days of the week were standardized within subjects 
and separated by three weeks.  For both sessions, subjects reported to the Exercise 
Physiology laboratory at 0800h.  Ambient light and temperature in the laboratory were 
held constant between 0800 and 2200h to control for their influence on circadian rhythm.   
During the SLEEP session, subjects were allowed adequate rest in a light controlled 
environment (2200 – 0600h) prior to exercise the next morning and investigators only 
entered the room briefly (<5min) to check on the subject.  If a subject was unable to 
remain asleep the entire night, they were asked to lie in bed in darkness until an 
investigator beckoned them at 0600h.  During the SLD session, subjects were sleep-
deprived by only allowing them to rest in wakeful state or pursue intellectual activities 
between the hours of 2200 to 0600h.   They were kept sedentary throughout the session, 
but were allowed to read, study and watch movies.  Researchers maintained social 
interaction with the subjects throughout the entire sleep deprived session.  During this 
time, the ambient light was unchanged from daylight hours.   
Body Composition Measurements   
During the first randomized laboratory session, subjects had their body 
composition assessed via whole body dual-energy X-ray absorptiometry (DXA) scan 
(Lunar-Prodigy Advance Plus, GE) at 0900h.  All scans were performed in fan beam 
mode using the thick scan mode (recommended by GE for research purposes; scan time 
was approximately 20 minutes).  Bone area (BA), bone mineral density (BMD), bone 
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mineral content (BMC), fat mass (FM) and fat-free mass (FFM) were measured for the 
whole body and regional areas.   
Standardized Caloric Intake  
A detailed dietary log was recorded for each subject 72 hours prior to and through 
the conclusion of each session and then analyzed for total calories using 
myfitnesspal.com®.  No caffeine or alcohol was allowed for the 48 hours preceding 
laboratory studies through the completion of the 24-hour session.  Daily caloric intake 
was standardized during each session for all subjects based on their estimated basal 
metabolic rate using the Harris Benedict Principle (101) (BMR = [66.4730 + 13.7516 x 
weight {kg}] + [5.0033 x height {cm}] – [6.7550 x age {yr.}] * [physical activity]).  
Each subject was instructed to eat within ~600 kcal of their pre-determined daily caloric 
intake each time they came to the laboratory and to stay consistent with their meals 
during each subsequent session.  At 2000h, subjects were given a standardized ~600 kcal 
snack that had a macronutrient content of  ~45% carbohydrate, ~20% protein and ~35% 
fat.  Following their snack, subjects fasted throughout the remainder of their session 
(2000 – 0900h).  
Exercise Testing Protocol   
Upon catheter insertion at 0600h, subjects rested passively in a chair while flow 
meters and gas analyzers were calibrated for collection of metabolic measurements using 
open circuit spirometery [(TrueOne® metabolic measurement system from ParvoMedics 
(Sandy, UT).  After 20 minutes of passive rest, subjects were fitted with their headgear to 
initiate gas collection while they continued to rest in an upright seated position for 
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another 25 minutes to insure accurate resting metabolic rate (RMR) data collection post-
catheter insertion.  Forty-five minutes into their passive rest period subjects completed a 
5-minute standardized submaximal warm-up that consisted of pedaling on a cycle 
ergometer at: 60 watts (W) for 4 minutes, 80 W for 30 seconds and 100 W for 30 
seconds.   At 0700h, subjects completed four maximal 30-second sprints against an 
electronically applied resistance on a cycle ergometer equivalent to 7.5% of their body 
weight (kg).  Each sprint was followed by four minutes of active recovery on the cycle 
ergometer.  Subjects were verbally encouraged to give maximal effort during the acute 
exercise tests.  Following the last exercise sprint, subjects continued to pedal for four 
minutes at the same active recovery workload of 50 W.   Average mean power (MP), 
peak power (PP), time to peak power (TTPP), minimum power (MinP), fatigue index (FI) 
and total work per sprint (TWPS) were calculated from all four sprints within each 
session.  FI was calculated from the average decline in peak power over minimum power 
during each sprint.  Ratings of self-perceived exertion (RPE) were recorded at the end of 
each exercise sprint and heart rate was assessed throughout testing using a Polar 
RS8000CX-N heart rate monitor and then furthered analyzed using the Polar 
ProTrainer5® software (Polar, USA, Lake Success, NY).  
Psychomotor Vigilance Task (PVT)   
The PVT is a reaction test that measures the speed of a subject’s response to a 
visual stimulus on a computer screen by clicking a button, thus implicating the central 
nervous system’s sensory sensitivity levels.  We used the adapted-duration version, 
lasting only 6.5 minutes, and subjects completed the task upon arrival to the laboratory at 
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0800h as well as 2000h, 0600h and again at ~0720h after the cessation of the last exercise 
sprint but just prior to the PASAT.  Due to the exhaustive nature of the exercise protocol, 
the tests were conducted post-exercise as soon as the subjects were stable enough to stand 
upright unassisted after a brief 5-min cool-down.  The average reaction time over the 
entire 6.5-minute test was used for statistical analysis.   
Paced Auditory Serial Addition Test (PASAT) 
The evaluation of cognitive processing performance (i.e. working memory) was 
assessed immediately following each PVT throughout each session using the Paced 
Auditory Serial Addition Test (PASAT).  The PASAT is a measure of cognitive function 
that uses auditory information processing speed to challenge working memory by having 
subjects add consecutive numbers in their head and give a verbal response (97).  The test 
was presented to the subjects on a pre-recorded disc and single digits were presented in 
an auditory format every three seconds while the subjects added each new number to the 
one immediately before it.  The test was scored by the number of the correct additions 
over the three minute test.  
Blood Lactate Sampling and Analysis 
Blood was collected by a trained technician through a catheter inserted into an 
arm vein in the antecubital space.  Blood samples were taken at rest 30 minutes pre-
exercise and immediately following the conclusion of the last exercise sprint (14 minutes 
post-exercise onset).   Blood samples were allowed to clot at room temperature for 30 
minutes.  Samples were then centrifuged at 3000 rpm for 15 minutes at 4ºC.  Serum was 
extracted and pipetted into microcentrifuge tubes and stored at -80ºC until subsequently 
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analyzed.  The samples were measured in duplicate and compared to standard controls 
using a modified version of the Hohorst assay (111) to enzymatically determine lactate 
concentration (Sigma-Aldrich) using a Shimadzu 1800 Spectrophotometer at a 
wavelength of 360 nm. 
Statistical Analysis  
Sleep (self-reported average amount of sleep per night) patterns prior to and 
during each session were examined using a paired-sample t-test.   When data was non-
normally distributed, a nonparametric Wilcoxon signed-rank test was used to adjust for 
the skewed distribution.  
Mean power (MP), peak power (PP), minimum power (MinP), time to peak 
power (TTPP), fatigue index (FI), and total work per sprint (TWPS) were calculated from 
each of the sprint exercise tests.  A repeated measures ANOVA was used to examine if 
differences existed in performance between sessions (main effect – session) and between 
the average sprint performance score in each session (main effect – sprint).  When the 
assumption of sphericity was violated, the Greenhouse-Geisser correction was used.  
When significant ANOVA effects were indicated, data descriptives were further 
examined using a paired samples t-test with a Bonferronni adjustment.  Overall combined 
total work (TW) of all four sprints (inclusive of the entire exercise session) was examined 
using a paired samples t-test with a Bonferronni adjustment as well.  
Resting heart rate was obtained by averaging the R-R intervals over 30 minutes of 
rest using the Polar ProTrainer5® software (Polar, USA, Lake Success, NY).   Fifteen 
second breath-by-breath averages of oxygen consumption (VO2), carbon dioxide (VCO2), 
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metabolic equivalents (METS), respiratory rate (RR), ventilation (VE), tidal volume (VT) 
and respiratory exchange ratio (RER) were calculated from open circuit spirometery for 
30 minutes prior to exercise through the end of exercise (Q-30 to Q15; 0630h – 0715h).  
Peak oxygen uptake (VO2peak) and highest attained exercise-induced peak HR was also 
recorded.  A paired-sample t-test was used to determine whether there were any 
differences in physiological data during rest and exercise values between the sessions.  
When data was non-normally distributed, a nonparametric Wilcoxon signed-rank test was 
used to adjust for the skewedness.   
A repeated measures ANOVA was used to evaluate the main and interaction 
effects of exercise and session on blood lactate concentrations pre- and post-exercise.  
When significant ANOVA effects were indicated, data descriptives were further 
examined using a paired samples t-test.  
Analysis of cognitive functioning test data (PVT & PASAT) was also done in a 
stepwise fashion.   An analysis of covariance (ANCOVA) was first used to examine test-
retest reliability because there were multiple (4) test retakes within a given session and 
was thus used to measure changes in test scores over time due to a possible “learning 
effect.”  This allowed us to examine the order of the cognitive test scores as a covariate to 
draw correct inferences about the influence of the dependent variable (cognitive test 
score) above and beyond the effects of the fixed factor (session) (i.e. did the session 
influence cognitive test scores if we control for the order that the tests was taken [at 
baseline, evening, pre/post-exercise]).  Then a repeated measures ANOVA was used to 
determine if differences in performance existed between the sessions (main effect – 
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session) and between the average cognitive test scores in each session (main effect – tests 
[1-4]).  Cognitive test scores were then examined to explain the significant effects of the 
using a paired-sample t-test within and between sessions.  When data was non-normally 
distributed, a nonparametric Wilcoxon signed-rank test was used to adjust for the 
skewedness. 
All results are expressed as mean ± standard deviation (SD), unless otherwise 
stated. The level of statistical significance is set at p < 0.05.  All statistical analysis was 
performed using PASW for Windows, version 22.0 (Chicago, Illinois, USA).   
Results 
  All subjects self-reported normal routines of work and sleep and had experienced 
no transmeridian travel within the last three months.  Subjects did not experience sleep 
deprivation and demonstrated a normal sleep pattern over the previous 7 days as per their 
self-reported sleep recall logs.  The average amount of self-reported sleep in the 7 days 
prior to each SLEEP and SLD session was (7.92 ± 0.33 vs. 7.98 ± 0.39 hrs, p = 0.656, 
respectively).  The average amount of self-reported sleep 7 days prior to the SLEEP 
session itself was also similar (7.72 ± 0.14 vs. 7.92 ± 0.33 hrs, p = 0.166, respectively).  
Mean Epworth Sleepiness Scale scores were 6.4 ± 1.6, which was within the normal 
range (John, 1991).  
Anaerobic Performance 
For descriptive purposes, average anaerobic performance results between sessions 
are found in Table 3.1.  The repeated measures ANOVA indicated significant main 
effects for MP, PP, MinP, TWPS and the individual performance results of each sprint 
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are depicted in Figure 3.2(a-d).  More specifically, mean power significantly decreased 
within each session, F (3, 54) = 93.299, p < 0.01, eta2 = 0.838, but was similar between 
sessions, F (1, 18) = 0.178, p = 0.678, eta2 = 0.010, and there was no interaction effect of 
sprint order and session, F (3, 54) = 0.528, p = 0.655, eta2 = 0.028.  Paired samples t-tests 
with a Bonferronni adjustment revealed that mean power was significantly greater in both 
sessions during sprint 1 compared to sprints 2-4 (p < 0.01) and was significantly greater 
during sprint 2 compared to sprints 3-4 (p < 0.01) (Figure 3.1a).  Peak power 
significantly decreased within each session, F (3, 54) = 9.734, p < 0.01, eta2 = 0.342, but 
was similar between sessions, F (1, 18) = 0.021, p = 0.866, eta2 = 0.001; however there 
was an interaction effect of sprint order and session, F (3, 54) = 2.940, p < 0.05, eta2 = 
0.140.  A paired samples t-test with a Bonferronni adjustment confirmed that only the 
peak power output during sprint 1 of the SLEEP vs. SLD session was significantly 
greater (1207 ± 177 vs. 1150 ± 137 W, respectively, p < 0.01).  Paired samples t-tests 
with a Bonferronni adjustment revealed that peak power was significantly greater in 
sprint 1 in the SLEEP vs. SLD session (p < 0.01).  In the SLEEP session only, sprint 1 
was significantly greater compared to sprints 3-4 (p < 0.01) and was significantly greater 
during sprint 2 compared to sprints 3-4 (p < 0.01).  Minimum power significantly 
decreased within each session, F (3, 54) = 25.287, p < 0.01, eta2 = 0.584, but was similar 
between sessions, F (1, 18) = 0.002, p = 0.968, eta2 = 0.000, and there was no interaction 
effect of sprint order and session, F (3, 54) = 1.857, p = 0.158, eta2 = 0.091.  Paired 
samples t-tests with a Bonferronni adjustment revealed that minimum power was 
significantly greater in both sessions during sprint 1 compared to sprints 2-4 (p < 0.01) 
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and was significantly greater during sprint 2 compared to sprints 3-4 (p < 0.01). Time to 
peak power was similar within each session, F (3,54) = 1.356, p = 0.266, eta2 = 0.070, 
and between sessions, F (1, 18) = 2.406, p = 0.138, eta2 = 0.118, and there was no 
interaction effect of sprint order and session, F (3, 54) = 1.566, p = 0.208, eta2 = 0.080.  
Fatigue index was also similar within each session, F (3, 54) = 1.762, p = 0.165, eta2 = 
0.089, and between sessions, F (1, 18) = 0.071, p = 0.793, eta2 = 0.004, and there was no 
interaction effect of sprint order and session, F (3, 54) = 1.780, p = 0.162, eta2 = 0.060. 
Total work per sprint was significantly decreased within each session, F (3, 54) = 
93.299, p < 0.01, eta2 = 0.838, but was similar between sessions, F (1, 18) = 0.178, p = 
0.678, eta2 = 0.010, and there was no interaction effect of sprint order and session, F (3, 
54) = 0.528, p = 0.655, eta2 = 0.028.  Paired samples t-tests with a Bonferronni 
adjustment revealed that total work per sprint was significantly greater in both sessions 
during sprint 1 compared to sprints 2-4 (p < 0.01) and was significantly greater during 
sprint 2 compared to sprints 3-4 (p < 0.01).  Additionally, a paired samples t-test a with 
Bonferronni adjustment revealed that the combined total work per session was similar 
between the SLEEP vs. SLD session (63,399 ± 8,268 vs. 61,764 ± 9,056 W, p = 0.175, 
respectively) (figure 3.3).  
Physiological Data 
The resting cardiorespiratory data can be found in Table 3.2.  Resting HR was 
significantly greater following the SLEEP vs. SLD session (64 ± 8 vs. 60 ± 8 bpm, p < 
0.05, respectively).  Oxygen consumption (VO2), carbon dioxide (VCO2), metabolic 
equivalents (METS), ventilation (VE), tidal volume (VT) and respiratory exchange ratio 
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(RER) were not significantly different between sessions.  However, respiratory rate (RR) 
was significantly lower during the SLEEP session compared to the SLD session (13.7 ± 
3.2 vs. 14.8 ± 2.2 breaths/min, p < 0.05, respectively). The cardiorespiratory response to 
exercise data can be found in Table 3.3.  Paired samples t-tests revealed that the 
exericise-induced peak HR was significantly greater during the SLEEP vs. SLD session 
(182 ± 9 vs. 176 ± 9 bpm, p < 0.05).  Average VO2, METS, VCO2, VE, RER, RR, VT, 
peak VO2 and peak METS were all similar between sessions.   
Lactate   
The repeated measures ANOVA indicated that lactate was significantly greater 
following exercise within each sesssion, F (1, 18) = 206.296, p < 0.01, eta2 = .920, but 
was similar between sessions, F (1, 18) = 0.452, p = 0.510, eta2 = 0.024.  Furthermore, 
there was no interaction effect of exercise and session, F (1, 18) = 0.420, p = 0.534, eta2 
= 0.022.  Paired samples t-tests revealed that exercise significantly increased blood 
lactate concentrations over resting values during both SLEEP (M ± SEM) (1.54 ± 0.19 
vs. 17.15 ± 1.54 mmol 1-1, p < 0.01) and SLD (1.49 ± 0.14 vs. 15.79 ± 1.40 mmol 1-1, p < 
0.01) and SLEEP sessions.  However, no differences in blood lactate concentrations 
existed between SLEEP and SLD sessions at rest (1.54 ± 0.19 vs. 1.49 ± 0.14 mmol 1-1, p 
= 0.811) and immediately following exercise (17.15 ± 1.54 vs. 15.79 ± 1.40 mmol 1-1, p = 
0.467).   
Sensory Sensitivity 
ANCOVA results indicated that there was no learning effect within sessions, after 
controlling for the order the PVT tests were taken (morning 0900h, evening 2000h, pre-
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exercise 0600h & post-exercise 0720h), F (1,77) = 3.691, p = 0.058, eta2 = 0.046.  
Results from the repeated measures ANOVA revealed a significant interaction effect 
between test order and session, F (3, 54) = 3.551, p = < 0.05, eta2 = 0.165.  Polynomial 
contrasts indicated, in support of this, that there was a significant linear trend F (1, 18) = 
4.675, p < 0.05, eta2 = 0.206, reflecting the slower reaction time for the 4th PVT test.  A 
Wilcoxon signed-rank test confirmed this interaction effect between test order and 
session by revealing that the subject’s reaction time was slower in the post-exercise (4th) 
PVT of the SLD vs. SLEEP session (326 ± 37 vs. 298 ± 21 msec, p < 0.01, respectively) 
(Figure 3.4). 
Cognitive Processing Performance 
ANCOVA results indicated that no learning effect occurred within sessions after 
controlling for the order the PASAT tests were taken, F (1,77) = 0.000, p = 0.989, eta2 = 
0.000.  Results from the repeated measures ANVOA confirmed that the subjects did not 
score differently (no significant main effect of test order) on the PASAT tests during the 
same 24-hour session, F (3, 54) = 0.057, p = 0.982, eta2 = 0.003 or between sessions, F 
(1, 18) = 0.107, p = 0.748, eta2 = 0.006, table 3.6.  In addition, there was no interaction 
effect between session and test order, F (3, 54) = 0.2.393, p = 0.079, eta2 = 0.117.  
Therefore, results indicate no significant differences in cognitive processing performance 
(Figure 3.5).   
Discussion 
Although sleep deprivation is pathologically associated with persons experiencing 
sleep disorders, sleep deprivation also commonly occurs in healthy individuals including: 
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athletes (especially ultra-endurance or adventure race competitors), students in higher 
education, night shift workers, or those in military training exercises.  We believe we are 
the first to examine the effects of complete sleep deprivation on high-intensity anaerobic 
exercise and subsequent effects on cognitive function.  Subjects completed an exercise 
battery that consisted of maximal high-intensity bursts with short recovery periods.  Tests 
for sensory sensitivity (PVT) and cognitive processing performance (PASAT) were 
measured four times throughout two separate 24-hour sessions involving a randomized 
night of adequate sleep vs. complete sleep deprivation.   
Anaerobic Performance 
Aerobic exercise of long duration results in decreased exercise performance 
following sleep deprivation (160).   However, more discrepancies arise as the exercise 
bouts become shorter in duration (44, 138).  Some researchers have adopted a “time 
course to failure” model and have reported that the time to failure decreases following 
sleep deprivation (247).   As the exercise protocol starts to rely more on the anaerobic 
systems, the results of the affects of sleep deprivation on performance appear to have a 
lesser effect.  Several studies using different anaerobic testing modalities have reported 
that sleep loss of 12 – 64 hr does not affect anaerobic performance (177, 238, 241).   The 
30 s Wingate test is a very popular exercise test used to measure anaerobic performance.  
During sleep deprivation, anaerobic performance following a single 30 s Wingate test 
was not affected (107, 227, 268).  
In the current study, anaerobic performance (mean power, peak power, minimum 
power and total work per sprint) diminished from sprint 1 to sprint 4 of the same exercise 
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session.  These results were to be expected, considering the maximal effort given with 
short recovery periods and that maximal voluntary force production is known to decrease 
rapidly with exercise (170).   However, time to peak power was similar between each 
sprint.  Fatigue index (defined by the average change in peak power over minimum 
power during each successive sprint) also did not change from sprint 1 to sprint 4, but 
this was a function of evenly decreasing peak and minimum power outputs during each 
sprint.   The only anaerobic performance measure that had an interaction effect with 
sprint order and session was peak power.  Figure 3.2(b) shows that peak power during the 
SLD session was similar across all four sprints unlike the peak power results from the 
SLEEP session where peak power was significantly greater during the 1st sprint compared 
to others.  A possible explanation for lower peak power the first sprint following sleep 
deprivation might be related to peripheral (neuromuscular) fatigue (27, 241).  Temesi et 
al. (247), exercised subjects for 40 minutes at 50-65% of their peak power output 
followed by a subsequent exercise test to exhaustion.  They reported that only cycling 
time to complete exhaustion was shorter during the sleep deprivation session.  Since we 
did not exercise subjects submaximally prior to the first exhaustive exercise sprint, 
neuromuscular fatigue was unlikely a factor during the first sprint and it is known that 
peak power during a Wingate anaerobic test represents the greatest maximal voluntary 
contraction occurring within the first 2 – 5 seconds.   This reflects the ability of the ATP-
PC system.  Since we didn’t assess the function of this system, we can only speculate that 
sleep deprivation may have an affect on the ATP-PC system, but because mean power 
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was similar for all four sprints between sessions, we can’t suggest that anaerobic 
performance, via glycogenolytic capacity was affected by sleep deprivation.   
Souisse et al. (227) demonstrated that peak power decreased during a single 
Wingate test but not until after 36 hours of sleep deprivation and they contributed this 
performance decriment to increased anxiety.  Although diminished anaerobic 
performance can’t be fully explained by measures of self-reported anxiety, we can’t rule 
out that it may also have played a contributory role to the greater peak power during 
sprint 1 of the SLEEP session.  In the current study, self-perceived exertion and verbal 
encouragement were similar during both sessions and this was likely because each 
Wingate test was very short in duration and each 30-second all-out sprint on the cycle 
ergometer brought each subject to complete exhaustion.  Additionally, it is also possible 
that there was a “ceiling effect” on self-perceived exertion during exercise, considering 
that the absolute workload was so great that subjects may have had a hard time 
distinguishing true exertion levels.  
Lactate  
McMurray and Brown (162) demonstrated lower concentrations of lactate during 
80% VO2max exercise following 24-hr sleep deprivation and suggested there was greater 
lactate turnover needed to maintain a wakeful state during sleep deprivation.  Mougin et 
al. (179) reported an upward drift in lactate release during submaximal exercise following 
partial sleep deprivation, but not until the 9th minute of a 20 minute bout at 75% VO2max.  
However, Vardar et al. (268) demonstrated that 24 or 36 hours of sleep deprivation did 
not affect blood lactate concentrations following a single Wingate test.  They suggested 
	  
68	  
	   	  
that the 30-second Wingate test was probably not sufficient to induce maximal utilization 
of anaerobic glycogenolytic potential.  When comparing our blood lactate response to the 
values obtained in Vardar et al. (268), we believe that our repetitive high-intensity 
protocol was sufficient in reaching glycogenolytic activation and furthermore, our high 
lactate values following exercise were expected considering the successive maximal 
exercise bouts.  Two points to consider are that the key factor in analyzing exercise-
induced changes in lactate concentrations is related to sample timing and exercise 
intensity.  Exercise of greater intensity with shorter recovery periods obviously creates a 
larger oxygen deficit and a state of metabolic acidosis in the muscle.  This correlates with 
less time for available oxygen uptake in exercising muscle leading to greater lactate 
production.  Our post-exercise sample for blood lactate concentration was taken 
immediately following the 4th successive Wingate test with only four minutes of recovery 
between each sprint.   This, along with the supramaximal strenuous exercise protocol, 
likely explains our high blood lactate concentrations.  Regardless, no differences existed 
between SLEEP and SLD sessions, suggesting that 1) blood lactate concentrations are not 
affected by sleep deprivation or 2) the supramaximal effort required for our exercise 
protocol was powerful enough to overshadow any possible effects of sleep deprivation on 
blood lactate accumulation. Large blood lactate concentrations, associated with a state of 
metabolic acidosis, can be indicative of respiratory acidosis producing greater carbon 
dioxide exhalation (VCO2).  However, VCO2 was similar between sessions and based on 
this theory, we can’t suggest that blood lactate concentrations were affected by sleep 
deprivation in the current study.  Additionally, respiratory acidosis can occur with or 
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without the presence of normal bicarbonate levels, suggesting that respiratory acidosis 
and metabolic acidosis are independents states and can’t be differentiated solely by 
increases in blood lactate concentrations.  
Physiological Measures 
In the present study, all physiological variables were similar at rest with the 
exception of respiratory rate (RR) and heart rate (HR).  Chen (44) reported that 
ventilation, a product of RR, was accompanied by an increase in CO2 production 
following 30-hr of sleep deprivation.  However, in the current study, RR was 
significantly higher at rest during sleep deprivation with no change in CO2 production.  
The mechanism by which sleep deprivation affects ventilation in young, healthy 
individuals at rest during sleep deprivation is still unknown.  Regardless, exercise 
abolished the difference in RR during sleep deprivation.  Although it has been suggested 
that sleep deprivation may cause respiratory acidosis leading to the impairment of the 
ability to respond to hypercapnia or hypoxia that may present itself during strenuous 
exercise (207), it is more likely that the drive to ventilate during exercise overpowers any 
affects of sleep deprivation.    
Similar to our results, other studies have reported lower resting HR during sleep 
deprivation and it has been suggested that lower levels of circulating catechomalamines 
may be a factor (31, 44).  The fact that respiration rate and heart rate were both affected 
by sleep deprivation at rest is interesting considering that ventilation influences the 
sympathetic axis.  Under normal resting conditions, parasympthatetic drive dominates 
cardiovascular response; however, there is a slight sympathetic influence that, if altered 
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by sleep deprivation, may be enough to be the proprietor of the small change in resting 
HR.  
Studies have reported ambiguous results of exercise-induced HR during sleep 
deprivation employing a wide range of submaximal exercise intensities with varying 
durations (44, 138, 158; 197, 207, 223).  During an exhaustive exercise test to failure 
following sleep deprivation, Temesi et al. (247) reported that the exercise-induced peak 
HR was ~7 bpm lower compared to a night of adequate rest.  Similarly, our peak HR 
response during short-term, high-intensity exercise was ~6 bpm lower during the SLD 
session even though total exercise workload was similar between sessions.  Two 
important factors may be related to the lower peak HR response during exercise 
following complete sleep deprivation including 1) a difference in exercise workload and 
associated changes in neuromuscular activation, and 2) an altered adrenergic response to 
exercise. Typically, greater exercise workloads usually depend on the activation of 
additional muscle tissue.  Temesi et al. (247) reported that maximal peripheral voluntary 
muscle activation decreased by 7% during their exhaustive exercise test to failure.  In our 
study, subjects all exercised for the same amount of time and also completed the same 
amount of total work for each 30-s sprint.  Therefore, unlike Temesi et al. (247), we can’t 
imply that the differences in exercise-induced peak HR were related to neuromuscular 
fatigue or exercise workload.  Furthermore, Martin & Chen (157) reported that 
circulating catecholamines during exercise were unaltered by sleep deprivation 
suggesting that the exercise-induced HR response during sleep deprivation appears to be 
more complicated.  Sleep deprivation may override the adrenergic response during 
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submaximal exercise per se, but to our knowledge, no one has reported the effects of 
sleep deprivation on the adrenergic response during short-term, high-intensity exercise.  
Since we did not measure plasma catecholamines, we can only speculate that sleep 
deprivation influences catecholamine release during short-term, high-intensity exercise.   
Most reports on exercise oxygen consumption during sleep deprivation are 
equivocal and differences in results appear to be based on experimental design (44, 138, 
158), however, several studies reported that sleep deprivation has no effect on oxygen 
consumption at various levels of intensity (157, 160, 197).  When exercise intensity is 
very low, detriments in exercise performance following sleep deprivation can still present 
themselves; however, it can take even longer before any significant changes occur.  
Martin et al. (159) walked subjects lightly on a treadmill following 36 hours of sleep 
deprivation and it took 3 hours before oxygen consumption was decreased.  In contrast, 
we found no significant differences in oxygen consumption during short-term exercise 
lasting ~14 minutes.   This may be attributed to the fact that the exercise protocol we 
utilized was not only short in duration, but also anaerobic in nature.  Thus, peak oxygen 
consumption was not expected to reach that of aerobic levels and it is less likely that 
sleep deprivation had an effect on anaerobic performance during short-term, high-
intensity exercise. 
Sensory Sensitivity 
The validity of the PVT has been extrapolated to cognitive processing, 
neurobehavioral changes in attention and used to identify performance degradation in 
fatigue-related conditions such as sleep deprivation (19).  Exercise can improve cognitive 
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function; especially sensory sensitivity measured by simple reaction time tests (110).  It 
must be noted that we did not conduct our cognition tests during exercise due to the 
maximal effort required for the protocol and thus, our results compared to similar studies 
employing cognitive tests during submaximal exercise must be interpreted with caution.  
Regardless, we found that PVT scores were not improved post-exercise during the 
SLEEP session.  This may have been the result of the time course of adaption for 
improvements in sensory sensitivity to occur.  Our high-intensity, short-term exercise 
bout lasted a maximum of 14 minutes with only 2 minutes of actual combined exercise 
(4x 30-s sprints).  Lambourne et al. (146) conducted a time-course adaptation experiment 
on the effects of steady-state exercise on sensory sensitivity and reported that the 
sensitivity response occurs gradually during steady-state submaximal exercise for at least 
15-20 minutes and stayed elevated during post-exercise recovery. Perhaps the short 
exercise duration in the current study and/or the post-exercise testing time frame was not 
sufficiently long enough to witness sensory sensitivity improvements during the SLEEP 
session.   In contrast, sensory sensitivity declined in the post-exercise PVT test during the 
SLD session.   One study that reported a restoration of sensory sensitivity post-exercise 
following sleep deprivation also reported that sleep deprivation impaired sensory 
sensitivity at rest (247).   In the current study, we found no difference in PVT scores at 
rest following sleep deprivation and thus, there was no possibility for the restoration 
effect to occur during post-exercise recovery. Secondly, the strenuous exercise protocol 
used in the current study could have been too much of a physical stressor on cognitive 
function and the decline in PVT scores may have been the result of an interaction effect 
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between sleep deprivation and mental, not physical fatigue from exercise (i.e.. despite 
what the subjects indicated, there was greater mental fatigue caused by the amount of 
internal motivation required to complete the maximal exercise protocol).  Lastly, one 
can’t rule out that the exercise stimulus was not sufficient to override sensory degradation 
caused by loss of sleep.  It is interesting to note that local increases in brain glucose 
utilization is observed in response to the stimulation of visual, auditory and other 
somatosensory pathways (86, 224).  It is theoretically possible that a strenuous and 
glycolytically exhaustive exercise protocol could severely impair glucose availability in 
the brain and thus, have a negative effect on sensory sensistivity.  Although the same 
exercise protocol was utilized during both sessions in the current study, there may be an 
interactive effect of sleep deprivation and exercise on brain metabolism leading to 
decriments in cognitive performance.  
Cognitive Processing 
Conflicting evidence on the effects of exercise on cognitive performance exists in 
the literature and is largely influenced by study design (72).  Although Audiffren et al. 
(13) reported that the first few minutes of exercise on a cycle ergometer could draw upon 
available attention resources and negatively influence processing ability, the current 
study reported that exercise had no effect on PASAT scores indicating that cognitive 
processing skills were unaffected by sleep deprivation or exercise.  The fact that 
cognitive performance was unaffected by sleep deprivation in the current study is not 
alarming, considering its been reported that night shift and overnight call duty workers 
can overcome sleep-loss related performance difficulties in cognitive processing for short 
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periods of time, even without an exercise stimulus (215).   On the contrary, some believe 
exercise may indeed act as a stimulus to enhance cognitive processing, especially during 
exercise recovery (251).  There are several reasons that may have resulted in our lack of 
significant differences between sessions.  First, perhaps if we would have re-tested 
subjects with the PASAT for several minutes post-exercise into recovery, we would have 
seen significant results as their may be a different time course of adapation for beneficial 
cognitive processing effects to present themselves following maximal anaerobic exercise.  
This is unlikely, however, considering that the upregulation of cognitive processing 
following exercise is short-lived (14).  Secondly, our findings may have been the result of 
a “ceiling effect” reported in similar studies.  Regardless of the steady-state exercise 
employed by Lambourne et al. (146), compared to high-intensity short-term exercise 
employed by the current study, we also had subjects with near-perfect PASAT scores 
from the very first test.  This resulted in little room for cognitive performance 
improvements.  Although we used an analysis of covariance to control for the order the 
tests were taken to examine test-retest reliability and found no “learning effect” in the 
current study, there did appear to be “near-maximal” scores for all tests in both 
conditions.  Perhaps if we used an alternate form of the PASAT [shorter intervals 
between numbering sequences (i.e. 2 sec vs. 3 sec)] to assess changes in cognitive 
processing during sleep and exercise it would have been a better test for our young, 
cognitively normal population.  Lastly, we always employed the PVT test first, followed 
immediately by the PASAT.  There is a possibility that the order of these tests had an 
influence on their results due to the PVT test enhancing behavioral alterness and 
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attentional focus that could have improved cognitive processing capability shortly 
thereafter.      
Conclusion 
Although average peak power was similar between sessions, there was a 
significant interaction effect of sleep and exercise on the peak power output during the 
first Wingate test during the SLEEP session.  However, the overall results indicated that 
average anaerobic performance was not influenced by sleep deprivation.  These results 
are similar to previously reported research suggesting that anaerobic power is unaffected 
by sleep deprivation (107, 177, 238, 241, 268).  Although it is unlikely that 
neuromuscular fatigue was influenced by sleep deprivation, we can’t rule out that sleep 
deprivation may have an affect on the ATP-PC system.  However, because mean power 
was similar for all four sprints between sessions, we can suggest that anaerobic 
performance, via glycogenolytic capacity was affected by sleep deprivation. Additionally, 
even though subjects reported no differences in self-percieved exertion and subjects were 
similarly motivated to give their best effort between sessions, there may be a possible 
“ceiling effect” of exertion at greater workloads of anaerobic exercise. 
Considering that heart rate was lower at rest and respiration rate was reciprocally 
elevated during sleep deprivation suggests that the ventilatory drive that influences heart 
rate may be altered by sleep deprivation at rest.   Although lower sympathetic drive 
(lower plasma catecholamine levels) may also suggest a lower resting heart rate during 
sleep deprivation, it can’t explain why strenuous exercise could not “jumpstart” 
sympathetic drive as it does following a night of adequate rest, similar to respiration rate. 
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Likely, other factors such as neuromuscular activation and an altered adrenergic response 
may have an interaction effect with sleep deprivation resulting in the attenuated heart rate 
response to strenuous exercise. However, the ventilatory drive caused by strenuous 
exercise may overpower the effects of sleep deprivation.    
Finally, the effects of exercise and sleep deprivation on cognitive performance 
may be task-specific.  Results of our study suggest that sleep deprivation (and its 
subsequent effects on central fatigue) may have a greater inhibitory effect than physical 
fatigue caused by exercise on tasks that involve sensory sensitivity but not cognitive 
processing.  It is obvious that the strenuous exercise bout induced symptoms of physical 
fatigue, but the metabolic challenge of the exhaustive exercise protocol may also have 
promoted central fatigue as well.  Future research should explore the interaction between 
glucose availability in neuronal tissues in relation to muscle glucose stores during 
exercise and sleep deprivation.  The interaction of these two factors could have resulted 
in the lower post-exercise PVT scores.   Although exercise during sleep deprivation 
impaired sensory sensitivity, cognitive processing ability was unaffected.  However, our 
cognitive test results should be interpreted with caution due to our possible “ceiling 
effect” of test scores.   
Sleep is a complicated process that affects cardiorespiratory response and 
cognitive function on several different levels. Future research needs to employ strategic 
protocols to examine the most beneficial type of exercise during times of sleep loss to 
promote peak anaerobic performance and cognitive function.  With the challenge of 
modern day sleep management at its greatest in today’s society, sleep-deprived 
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individuals of all different backgrounds would benefit in understanding the mechanistic 
underpinnings of the interaction between mental and physical fatigue induced by sleep 
deprivation and how proper exercise prescription may be a sufficient tool for minimizing 
impairments in cognitive function.  
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Table 3.1. Sprint Performance Between Sessions (M ± SD).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable SLEEP SLD 
Mean Power (W) 528 ± 69 515 ± 75 
Peak Power (W) 1131 ± 198 1118 ± 183 
Minimum Power (W) 271 ± 69 272 ± 71 
Time to Peak Power (sec) 1.1 ± 0.4 0.9 ± 0.2 
Fatigue Index (%) 29.8 ± 5.9 29.1 ± 5.9 
Total Work per Sprint (W) 15850 ± 2067 15441 ± 2264 
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Table 3.2.  Resting Cardiorespiratory Data Over ~30 Min of Data Collection in a 
Seated Resting Position (M ± SD).   
     
Variable SLEEP SLD p Adjusted p** 
Heart rate (bpm) 64 ± 8 60 ± 8 0.033* - 
VO2 (L/min) 0.33 ± 0.05 0.35 ± 0.06 0.464 - 
VO2 (ml/kg/min) 3.8 ± 0.6 4.0 ± 0.7 0.435 - 
METS 1.1 ± 0.2 1.1 ± 0.2 0.430 - 
VCO2 (L/min) 0.33 ± 0.06 0.38 ± 0.08 0.082 - 
Ventilation (VE) L/min 13.5 ± 3.3 14.9 ± 3.3 0.282 - 
(RER) 1.0 ± 0.1 1.2 ± 0.3 0.252 0.333 
(RR) brths/min 13.7 ± 3.2 14.8 ± 2.2   0.027* - 
Tidal Volume (VT) L/min 1.1 ± 0.3 1.1 ± 0.3 0.888 - 
          
 
*p < 0.05.  **When data was non-normally distributed, p values were adjusted for 
skewedness (>1.0) using the nonparametric Wilcoxon signed-rank test.  (RR) – 
respiratory rate; (RER) – respiratory exchange ratio. 
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Table. 3.3. Cardiorespiratory Response to Repetitive Sprint Exercise (M ± SD).  
     
Variable SLEEP SLD p Adjusted p** 
Peak heart rate (bpm) 182 ± 9 176 ± 9 0.013* - 
VO2 (L/min)# 2.04 ± 0.43 2.04 ± 0.42 0.986 0.906 
VO2 (ml/kg/min)# 23.4 ± 4.1 23.4 ± 3.9 0.973 0.878 
METS# 6.7 ± 1.2 6.7 ±1.1 0.936 0.959 
VCO2 (L/min) # 2.48 ± 0.35 2.98 ± 1.14 0.181 0.415 
Ventilation (VE) L/min# 90.6 ± 26.7 80.4 ± 19.3 0.209 0.139 
(RER)# 1.4 ± 0.4 1.5 ± 0.5 0.724 0.374 
(RR) brths/min# 33.3 ± 5.3 31.1 ± 6.9 0.260 - 
Tidal Volume (VT) L/min# 2.59 ± 0.68 2.53 ± 0.58 0.672 0.443 
VO2peak (L/min) 3.36 ± 0.59 3.52 ± 0.66 0.388 - 
VO2peak (ml/kg/min) 38.3 ± 4.7 39.9 ± 4.7 0.434 - 
METSmax 11.0 ± 1.4 11.4 ± 1.3 0.436 - 
          
 
#average values over ~15 minutes of exercisedata collection. **When data was non-
normally distributed, p values were adjusted for skewedness (>1.0) using the 
nonparametric Wilcoxon ranked signs test for two related samples.  (RR) – respiratory 
rate; (RER) – respiratory exchange ratio. 
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Figure 3.1.  Experimental Protocol Showing the 24-Hr Laboratory Sessions.  The design 
was counter-balanced and randomized between sessions.   
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Figure 3.2a.  Mean Power Output (W) During Sprint Exercise Between Sessions.  Paired 
samples t-tests with a Bonferroni adjustment revealed that mean power was significantly 
greater in both sessions during sprint 1 compared to sprints 2-4, p < 0.01* and was 
significantly greater during sprint 2 compared to sprints 3-4, p < 0.01 #.  
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Figure 3.2b. Peak Power Output (W) During Sprint Exercise Between Sessions.  Paired 
samples t-tests with a Bonferroni adjustment revealed that peak power was significantly 
greater in sprint 1 in the SLEEP vs. SLD session, p < 0.01^.  In the SLEEP session only, 
sprint 1 was significantly greater compared to sprints 3-4, p < 0.01* and was significantly 
greater during sprint 2 compared to sprints 3-4, p < 0.01 #.   
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Figure 3.2c.  Minimum Power Output (W) During Sprint Exercise Between Sessions.  
Paired samples t-tests with a Bonferroni adjustment revealed that minimum power was 
significantly greater in both sessions during sprint 1 compared to sprints 2-4, p < 0.01* 
and was significantly greater during sprint 2 compared to sprints 3-4, p < 0.01 #.  
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Figure 3.2d.  Total Power Output Per Sprint (W) Between Sessions.  Paired samples t-
tests with a Bonferroni adjustment revealed that total work per sprint was significantly 
greater in both sessions during sprint 1 compared to sprints 2-4, p < 0.01* and was 
significantly greater during sprint 2 compared to sprints 3-4, p < 0.01 #.  
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Figure 3.3.  Combined Total Work (W) From All Four Sprints.  Total work was similar 
between the sleep (SLEEP) and sleep deprivation (SLD) sessions.   
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Figure 3.4. Psychomotor Vigilance Task (PVT) Scores Between Sessions.  # Repeated 
measures ANOVA indicated that there was a significant interaction effect between test 
order (1-4) and session, p < 0.05.  A Wilcoxin signed-rank test confirmed that reaction 
time was slower during the 4th PVT test of the SLD compared to the SLEEP session (p < 
0.01)*.  
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Figure 3.5. Paced Auditory Serial Addition Test (PASAT) Scores Between Sessions.  
ANCOVA results indicated no effect of test order on PASAT scores within session 
suggesting a lack of learning effect and good test-retest reliability.   Two-way analysis of 
variance with repeated measures indicates no differences in PASAT scores between 
SLEEP and SLD sessions.  
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Abstract 
 The effect of acute (24-hr) sleep deprivation on exercise-induced human growth 
hormone (GH) and insulin-like growth factor-1 (IGF-1) was examined. Ten male subjects 
(20.6 ± 1.4 years) completed two randomized 24-hour laboratory sessions with a brief, 
high-intensity exercise bout following either a night of adequate sleep (SLEEP) or acute 
(24-hour) sleep deprivation (SLD).  Anaerobic performance (mean power [MPOW], peak 
power [PP], minimum power [MinPOW], time to peak power [TTPP], fatigue index [FI]) 
and total work per sprint [TWPS]) was determined from four maximal 30-sec Wingate 
sprints on a cycle ergometer. The average amount of self-reported sleep in the 7 days 
prior to each session was similar between the SLEEP and SLD sessions (7.92 ± 0.33 vs. 
7.98 ± 0.39 hr, p = 0.656, respectively) and during the actual SLEEP session in the lab, 
the total amount of sleep was similar to the 7 days leading up to the lab session (7.72 ± 
0.14 hours vs. 7.92 ± 0.33 hours, respectively) (p = 0.166). No differences existed in 
MPOW, PP, MinPOW, TTPP, FI, TWPS, resting GH concentration, time to reach 
exercise-induced peak GH concentration (TTP), or free IGF-1 between sessions.  
However, GH area under the curve (AUC) (exercise + recovery), exercise-induced peak 
GH concentration and ΔGH (peak GH – resting GH) were significantly lower during the 
SLEEP session (p < 0.01).  Our results indicate that the exercise-induced GH response 
was significantly greater in sleep-deprived individuals.  
Keywords 
 sprint exercise • high intensity exercise • sleep loss • anaerobic  
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Introduction 
Humans have an endogenous timing system that is synchronized by their inherent 
circadian rhythm and sleep-wake cycle.  The circadian rhythm re-generates itself, on 
average, every 24 hours and creates a biological night and day that alternate in a cyclic 
fashion to mediate the timely release of hormones (52).  Human growth hormone (GH) is 
secreted from the anterior pituitary gland, which is heavily regulated by the 
hypothalamus and mediated by the effects of growth hormone-releasing hormone 
(GHRH), somatostatin (SMS), ghrelin (GHS) and insulin-like growth factor-1 (IGF-1).  
GH is secreted in a pulsatile fashion, with the greatest non-circadian stimuli being sleep 
and exercise.  However, as sleep progresses, the circadian clock is also changing.  This 
means the endogenous effect of the circadian rhythm on GH release is more difficult to 
distinguish because of the significant sleep-dependency of GH and the crossover effect 
between waking from sleep and circadian rhythm cyclic regeneration. By using the 
“constant routine” method, modified by Czielser et al. (52), researchers can dissociate the 
circadian rhythm from the sleep-wake cycle.  In this type of experimental design, subjects 
are sleep deprived by remaining awake for long periods of time in a semi-recumbent 
position in dim, indoor lighting, to minimize the influence of fluctuating patterns of light 
exposure on circadian rhythm and its subsequent effect on GH release.  Several studies 
have used this experimental design to manipulate sleep-wake cycles and examined the 
independent effects of circadian rhythm on GH.  These types of studies have reported 
minimal effects of circadian rhythm on GH secretion (35, 92, 166, 260-261).  
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Humans spend approximately one-third of their lives sleeping (176).  The major 
secretory GH pulse occurs just after sleep onset and continues to rise during the first 4 
hours.  Most GH release occurs during NREM (non-rapid-eye movement) sleep within 
the slow-wave sleep (SWS) phase with little GH secreted during REM (rapid-eye 
movement) sleep (115, 202, 221, 240, 260-261).   Sleep deprivation can alter 
hypothalamus and pituitary function, which de-synchronizes GH release timing (36, 39, 
73, 260, 297).  During complete sleep deprivation of 24-36 hours, GH release is 
attenuated and in some cases, absent (36, 39, 131, 221, 240).  Brun et al. (39) reported 
that GH release was dramatically reduced during a 36-hour sleep-deprived session with 
the most noticeable decrease in nocturnal GH peak values (28.2 ± 17.9 ug/l vs. 5.5 ± 3.4 
ug/l, for control and sleep deprivation sessions, respectively).  Peak nocturnal GH 
secretory bursts were observed in the subjects between 23:00 and 2:30 h during the 
control session.  During the sleep-deprived session, the nocturnal peak amplitude and 
total GH area under the curve (AUC) were dramatically reduced although the total 
number of GH peaks during the 24-hour sampling period was similar between the control 
and sleep-deprived session.  Brandenberger et al. (36) reported that 24-hr GH was 
unaffected by total sleep deprivation; however, they reported that the large amount of 
inter-individual variability may have been the reason why there was no statistical 
difference.  Additionally, they reported that GH pulsatility profiles were different 
between habitual sleepers and adapted night shift workers.  Not only was nocturnal GH 
release lower in adapted night shift workers, but also 24-hr GH pulsatility was more 
frequent, sporadic and unpredictable throughout waking hours.  
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Exercise is a proven stimulus of GH release and an acute bout of exercise 
stimulates a significant GH pulse (40, 45, 76, 89, 211-213, 237; 287-288, 293-296).   
Although there is large inter-individual variation in exercise-induced GH release, it is a 
reproducible measure within subjects (155, 235).  Alterations in exercise intensity and 
duration (equating to increases in workload) have been shown to increase the exercise-
induced GH response in a linear fashion (40, 45, 76, 89, 211-213, 237; 287-288, 293-
296).   Multiple studies have shown that shorter bouts of high-intensity exercise also 
elicit an elevated growth hormone response (129, 186, 231-234, 236).  Peak GH release 
occurs within ~30-45 minutes after the initiation of sprint exercise and a single 6-second 
sprint can augment GH release (234), although a slightly longer 30-second sprint 
enhances GH release further (186, 232, 234).   
To our knowledge, no one has examined the effects of acute (24-hr) sleep 
deprivation on exercise-induced GH release using short-term, high intensity exercise.  
Several studies examining the circadian rhythm effects on exercise-induced GH release 
employing various modes, intensities and durations of exercise have reported an increase 
in GH release regardless of the time of day the exercise was employed (85, 128, 255).  
This suggests that the exercise stimulus is powerful enough to override the naturally 
occurring cyclic downregulation in GH output that is triggered by the circadian rhythm.   
The two studies that have examined the effects of exercise-induced GH release during 
complete (24-hr) sleep deprivation and exercise-induced GH release during partial sleep 
deprivation have yielded inconsistent results largely due to methodological differences 
(1, 178). Considering GH release begins around the onset of sleep, partial sleep 
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deprivation may still provide sufficient rest to elicit a normal nocturnal GH release and 
thus, limit the alterations observed in subsequent exercise-induced GH release.  
Therefore, the purpose of this study was to investigate the effects of acute sleep 
deprivation on subsequent exercise-induced GH release. We hypothesized that GH 
release will be augmented during short-term, high-intensity exercise following a 24-hr 
period of continuous sleep deprivation.  
Methods 
Subject Characteristics  
Ten male subjects (9 Caucasian, 1 African-American and 1 Hispanic), ages 18 – 
22 yr (20.6 ± 1.4 yr) with an average body mass index of 26.6 ± 2.5 kg/m2, and body fat 
percentage of 20.9 ± 6.8 %, completed the study.  On average, subjects reported 
participating in high-intensity activity 1 day per week and spent 4 – 6 hours per week 
participating in recreational physical activity and reported minimal occupational physical 
work.  All subjects provided written informed consent in accordance with the institutional 
review board at the University of North Carolina at Greensboro and Winston-Salem State 
University.  All subjects underwent a strict preliminary screening session prior to 
inclusion.  Subjects were excluded if they: 1) had a body fat percentage >30%, 2) 
reported a history of hematological, renal, hepatic, metabolic or thyroid dysfunction, 3) 
were currently on a caloric restriction program (diet) or taking any medications that 
promoted weight loss, 4) currently smoked or had quit smoking within the previous three 
months, 5) had documented sleep disturbances or irregular sleeping patterns such as night 
shift work or recreational habits, 6) had completed transmeridian travel within the last 
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month, or 7) participated in greater than 10 hours of recreational activities (swimming, 
basketball, jogging, cycling etc.) per week or were involved in any type of sprint training 
within the last 6 months.  Self-reported sleep logs were kept for seven days prior to both 
24-hr laboratory sessions and were used to screen for normal sleep patterns.  Epworth 
Sleepiness scales were used to screen for baseline excessive subjective sleepiness and/or 
irregular sleeping habits (126).  Individuals who met the inclusion criteria completed a 
brief familiarization session on an electronically-braked cycle ergometer (Lode Excalibur 
Sport, Lode BV, Gronignen, The Netherlands).  Equipment used to collect metabolic 
measures using standard open circuit spirometry (TrueOne® metabolic measurement 
system from ParvoMedics [(Sandy, UT)] during exercise was fitted during this 
familiarization session, but no gases were collected.   
Experimental Design 
Subjects completed one baseline 24-hour laboratory session where their acute 
exercise response was measured following a night of sufficient rest and compared to the 
identical exercise-induced response following a 24-hour sleep deprivation session (Figure 
4.1).  Subjects were instructed to refrain from exercise the 48 hours prior to their 
randomized laboratory session.   In order to control for order effects, a counterbalanced 
design was used in which half the subjects performed the sleep deprivation session (SLD) 
first and the other half performed the control sleep session (SLEEP) first.  Testing days of 
the week were standardized within subjects and separated by three weeks.  For both 
sessions, subjects reported to the Exercise Physiology laboratory at 0800h.  Ambient light 
and temperature in the laboratory were held constant between 0800 and 2200h to control 
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for their influence on circadian rhythm.   During the SLEEP session, subjects were 
allowed adequate rest in a light controlled environment (2200 – 0600h) prior to exercise 
the next morning and investigators only entered the room briefly (<5min) to check on the 
subject.  If a subject was unable to remain asleep the entire period, they were asked to lie 
in bed in darkness until an investigator beckoned them at 0600h.  During the SLD 
session, subjects were sleep-deprived by only allowing them to rest in wakeful state or 
pursue intellectual activities between the hours of 2200 to 0600h.  They were kept 
sedentary throughout the session, but were allowed to read, study and watch movies 
researchers maintained social interaction with the subjects throughout the entire sleep 
deprived session.  During this time, the ambient light in the laboratory was unchanged 
from daylight hours.   
Body Composition Measurements 
During the first randomized laboratory session, subjects had their body 
composition assessed via whole body dual-energy X-ray absorptiometry (DXA) scan 
(Lunar-Prodigy Advance Plus, GE) at 0900h.  All scans were performed in fan beam 
mode using the thick scan mode (recommended by GE for research purposes; scan time 
was approximately 20 minutes).  Bone area (BA), bone mineral density (BMD), bone 
mineral content (BMC), fat mass (FM) and fat-free mass (FFM) were measured for the 
whole body and regional areas.   
Standardized Caloric Intake 
A detailed dietary log was recorded for each subject 72 hours prior to and through 
the conclusion of each session and then analyzed for total calories using 
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myfitnesspal.com®.  No caffeine or alcohol was allowed for the 48 hours preceding 
laboratory studies through the completion of the 24-hour session.  Daily caloric intake 
was standardized during each session for all subjects based on their estimated basal 
metabolic rate using the Harris Benedict Principle (101) (BMR = [66.4730 + 13.7516 x 
weight {kg}] + [5.0033 x height {cm}] – [6.7550 x age {yr.}] * [physical activity]).  
Each subject was instructed to eat within ~600 kcal of their pre-determined daily caloric 
intake each time they came to the laboratory and to stay consistent with their meals 
during each subsequent session.  At 2000h, subjects were given a standardized ~600 kcal 
snack that had a macronutrient content of  ~45% carbohydrate, ~20% protein and ~35% 
fat.  Following their snack, subjects fasted throughout the remainder of their session 
(2000 – 0900h).  
Exercise Testing Protocol 
Upon catheter insertion at 0600h, subjects rested passively in a chair while flow 
meters and gas analyzers were calibrated for collection of metabolic measurements using 
open circuit spirometery [(TrueOne® metabolic measurement system from ParvoMedics 
(Sandy, UT).  After 20 minutes of passive rest, subjects were fitted with their headgear 
and mouth pieces to breath through to initiate gas collection while they continued to rest 
for another 25 minutes to insure accurate resting metabolic rate (RMR) data collection 
post-catheter insertion.  Forty-five minutes into their passive rest period subjects, 
completed a 5-minute standardized submaximal warm-up that consisted of pedaling on a 
cycle ergometer at: 60 watts (W) for 4 minutes, 80 W for 30 seconds and 100 W for 30 
seconds.   At 0700h, subjects completed four maximal 30-second sprints on a cycle 
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ergometer against an electronically applied resistance equivalent to 7.5% of their body 
weight (kg).  Each sprint was followed by four minutes of active recovery on the cycle 
ergometer at 50 W.  Subjects were verbally encouraged to give maximal effort during the 
acute exercise tests and ratings of self-perceived exertion (RPE) were recorded at the end 
of each sprint.  Following the last exercise sprint, subjects continued to pedal for four 
minutes at the same active recovery workload of 50 W.   
Blood Sampling and Analysis 
Blood was collected by a trained technician through a catheter inserted into an 
arm vein in the antecubital space.  Catheter patency was maintained by displacing the 
blood in the catheter with isotonic saline at regular intervals.  A heating pad was placed 
over the antecubital area in order to further prevent peripheral vasoconstriction and 
maximize patency during the post-exercise period.  Blood samples were taken at 
seventeen different time points (Figure 4.2) and, on average, every 15 minutes (~Q15) for 
180 minutes, with more frequent sampling just prior to initiating the first exercise sprint 
and immediately after the 4th exercise sprint a post-exercise blood sample was collected.  
Blood samples were allowed to clot at room temperature for 30 minutes.  Samples were 
then centrifuged at 3000 rpm for 15 minutes at 4ºC.  Serum was extracted and pipetted 
into microcentrifuge tubes and stored at -80ºC until subsequently analyzed.  
Growth hormone from all time points were determined in duplicate using a human 
GH enzyme-linked immunosorbant assay (MP Biomedicals, Solon, OH).  The minimum 
detectable dose of this assay was 0.5 µg/L and the intra-assay variance was 2.2 – 2.9%.  
Insulin-like growth factor-1 (IGF-1) immediate pre-exercise and 120 minutes post-
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exercise onset (~106 minutes post-exercise) was assayed in duplicate using an in vitro 
enzyme-linked immunosorbent assay (Raybiotech, Norcross, GA). The minimum 
detectable dose of this assay was 0.1 µg/L and the intra-assay variance was <10%.  To 
eliminate inter-assay variance, all samples from a single subject were assayed within the 
same plate.   
Statistical Analysis 
Sleep (self-reported average amount of sleep per night) patterns prior to and 
during each session were examined using a paired-sample t-test.   Mean GH area under 
the curve (AUC) was calculated using the trapezoidal integration method.  Data from 
each time point was included in the calculation.  The AUC was calculated as previously 
described in detail by Stokes et al. (235).  Briefly, the intersection where the GH values 
and time points created an ordinate was joined to form a straight line that created a 
trapezium.  The area of each trapezium was calculated using the equation:  area = (y1 + 
y2) x 0.5 x d, where y1 + y2 are the GH concentrations at two successive time points and d 
is the time interval between the two samples.  A Wilcoxon signed-rank test was used to 
determine whether there were any mean differences in GH AUC, peak GH, time to peak 
GH, resting GH concentrations and ΔGH (peak GH – resting GH) between sessions.  
Peak values refer to the mean of the highest measured values for each individual.  Resting 
GH was determined by the average of the initial three time points (-60, -45, -30) 
preceding the exercise warm-up.  A repeated measures ANOVA, with Greenhouse-
Geisser correction, was conducted to assess whether there were differences between the 
average exercise-induced GH concentration between the SLEEP and SLD sessions (main 
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effect of session) and the response of each subject with respect to the 13 time points when 
blood draws occurred, starting at 0700h just prior to exercise onset (main effect of time).  
Whenever mean differences were observed, mean comparisons were examined using a 
Wilcoxon signed-rank test.  Test-retest (Pearson) correlations were used to indicate the 
rank order of peak GH concentration and GH AUC within and between subjects.  A 
repeated measures ANOVA was also used to determine any differences in free IGF-1 
before and after exercise.  The level of statistical significance was set at p < 0.05.  All 
statistical analyses were performed using PASW for Windows, version 22.0 (Chicago, 
Illinois, USA).  All results are expressed as means ± SEM, unless otherwise noted.  
Results 
All subjects self-reported normal routines of work and sleep and had experienced 
no transmeridian travel within the last three months.  Subjects did not experience sleep 
deprivation and demonstrated a normal sleep pattern over the previous 7 days as per their 
self-reported sleep recall logs.  The average amount of self-reported sleep in the 7 days 
prior to each session was similar between the SLEEP and SLD sessions (7.92 ± 0.33 vs. 
7.98 ± 0.39 hours, p = 0.656, respectively).  During the SLEEP session in the lab, 
subjects reported that they slept an average of 7.72 ± 0.14 hours, which was similar to the 
7 days leading up to the lab session (7.92 ± 0.33 hours) (p = 0.166) Mean Epworth 
Sleepiness Scale scores were 6.4 ± 1.6, which was within the normal range (John, 1991). 
As previously reported, overall anaerobic sprint performance did not differ between 
sessions and the total combined work of the entire exercise session was similar.   
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Growth Hormone 
 GH AUC (exercise + recovery), peak GH concentration and ΔGH were 
significantly lower during the SLEEP session (p < 0.01) whereas resting GH release and 
time to reach peak GH concentration did not differ between sessions (Table 4.1).  Results 
of the repeated measures ANOVA indicated a significant interaction effect between time 
point and session, F (1.957, 35.221) = 4.434, p < 0.05, eta2 = 0.198.  There were also 
significant main effects for time point, F (1.957, 35.221) = 25.450, p < 0.01, eta2 = 0.586, 
and session, F (1, 18) = 7.858, p < 0.05, eta2 = 0.304.  Figure 4.3 shows the mean GH 
concentrations during exercise + recovery, starting at exercise onset (0700h, i.e. time 
point 0), that included four successive 30 s maximal sprints with four minutes of active 
recovery on a cycle ergometer.  Wilcoxon signed-rank tests were used to further examine 
which average GH concentrations (by time point) differed between sessions.  Results 
indicated that exercise-induced GH concentrations were significantly lower during the 
SLEEP session from the onset of exercise (time point 0) through the remainder of the 
120-minute profile.  Additionally, exercise-induced GH values were significantly greater 
at each time point compared to resting GH values in both sessions and these remained 
greater throughout the entire 120-minute profile that included exercise and recovery.   
 Individual GH AUC and peak GH concentrations increased significantly in all 
subjects even though there was a large degree of inter-individual variation during both 
sessions (Figures 4.4 & 4.5).  This indicates that the subjects stayed within the same 
approximate rank response order during both sessions and this was confirmed by the 
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statistically significant test-retest correlations between sessions for both GH AUC (r = 
0.888, p < 0.01) and peak GH concentration (r = 0.845, p < 0.05).   
Free IGF-1 
A repeated measures ANOVA indicated that free IGF-1 was similar following 
exercise, F (1, 12) = 0.945, p = 0.350, eta2 = .073, and was also similar between sessions, 
F (1, 12) = 0.871, p = 0.429, eta2 = 0.053.  Furthermore, there was no interaction effect of 
exercise and session, F (1, 18) = 0.228, p = 0.642, eta2 = 0.019 (Figure 4.6).  
Discussion 
We believe the current investigation is the first to report the response of growth 
hormone to short-term, high-intensity exercise following acute (24-hr) sleep deprivation.  
The primary findings from the current study can be summarized as follows 1) early 
morning resting GH concentration was unaffected by sleep deprivation, and 2) exercise-
induced GH AUC, peak GH concentration and Δ GH (peak GH – resting GH 
concentration) were significantly greater following a night of sleep deprivation.  
The present study supports previous research that suggests short-term, high-
intensity exercise augments the GH response following a night of adequate sleep (129, 
186, 231-236) and partial sleep deprivation (1).   It has been proposed that intense 
physical activity combined with caloric and sleep restriction can amplify GH secretion 
(187).  However, few studies have attempted to examine the singular effects of acute 
sleep deprivation on exercise-induced GH release.  Abedelmalek et al. (1) reported that 
growth hormone was increased following partial sleep deprivation using repeated brief 
sprint exercises similar to the current study.  In Abedelmalek et al. (1), thirty healthy, 
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college-aged athletes exercised at 0800h after only being allowed to sleep from 2230 to 
0300h compared to our complete lack of overnight sleep during the SLD session.  During 
each of their exercise sessions, subjects completed 4 x 250-m runs on a treadmill at a 
constant intensity of 80% of an individualized maximal speed with 3-min recovery 
intervals. However, Abedelmalek et al. (1) failed to report significant elevatons in GH 
immediately post-exercise due to lack of post-exercise followup time points and the fact 
that the exercise-induced GH response was much less than the current study.  These 
differences are likely due to the partial and not complete (24-hr) sleep deprivation 
utilized by Abedelmalek et al. (1) and its subsequent effects on nocturnal GH release and 
feedback mechanisms.  For example, Mougin et al. (178) reported that partial sleep 
deprivation did not affect exercise-induced GH release.   However, in this study, subjects 
were awoken as soon as they were about to enter rapid-eye movement (REM) sleep 
unlike Abedelmalek et al. (1) that allowed subjects to sleep for 4 consecutive hours.  
They were kept awake by pursuing sedentary activities in bed for three hours before 
being allowed back to sleep until 0700h and remained sedentary until their exercise 
session at 0200h.  Within a normal episode of sleep, the first four stages constitute non-
rapid eye-movement (NREM) sleep and are made up of several cycling stages of 
consciousness and slow-wave brain activity.  Typically, most GH release occurs during 
this non-rapid eye movement (NREM) phase constituting slow-wave sleep (SWS) that 
occurs within these first 4 hours (131, 202, 221, 240, 260-261) with little GH secreted 
during subsequent REM sleep (115).  Thus, subjects in the Mougin et al. (178) and 
Abedelmalek et al. (1) studies were not sleep deprived during the SWS phase when most 
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nocturnal GH release occurs and this is likely the reason why exercise-induced GH 
release was similar in both admissions.  This is in agreement with a much earlier study by 
Karacan et al. (131), who reported lower GH concentrations during sleep deprivation in 
which subjects were awakened prior to entering SWS. 
Total GH AUC and peak GH concentration during the SLEEP condition were 
similar to previously reported research (232-235) but during the SLD session they were 
increased 2.7-fold and 2.2-fold, respectively.  Despite these large differences, there was 
still a large inter-individual variation in GH concentration (figure 4.4) and peak GH 
(figure 4.5).  Test-retest (Pearson) correlations of GH AUC and peak GH concentration 
between sessions in the current study were similar to those that were reported by Stokes 
et al. (235) (r = 0.89, p < 0.01; r = 0.85, p < 0.05 vs. r = 0.97 p < 0.05, r = 0.97, p < 0.05, 
respectively).  Stokes et al. (235) reported significant test-retest correlations when 
subjects performed one 30-s all-out sprint followed by 60 minutes of recovery on two 
separate occasions, separated by 7 days.  However, our test-retest correlations were 
similar across two separate conditions (SLEEP vs. SLD).  This likely represents the rank 
response order within subjects (i.e. those that a large GH response during the SLEEP 
session also had a large, yet amplified GH response during the SLD session).  Therefore, 
the slightly lower test-retest correlations in our study depict the augmentative GH 
response interactive effects of sleep deprivation. 
Stokes et al. (234) examined the exercise-induced GH response after 6 and 30 
seconds of maximal cycling exercise using a resistance equivalent to 7.5% of the 
subject’s body mass.  There were no differences between the power outputs of the 
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participants within the first 6s of either a 6s or 30s trial.  Serum GH concentrations were 
elevated after both trials, however the magnitude of the elevation after the 30s sprint was 
much greater than the 6s sprint.  Serum GH peaked at 40 min post-exercise in both trials 
and remained elevated for 60 min after the 6s sprint and 90-120 min after the 30s sprint.  
The 30s sprint produced elevations in GH of 18.5 ± 3.1 µg/L at peak, an increase of 
530% from baseline, whereas the 6s sprint produced a GH concentration of only 4.0 ± 1.5 
µg/L at peak concentration or 217% above baseline concentration.  This represented a 
450% greater maximal GH concentration release during the 30s vs. the 6s trial.  Stokes et 
al. (233) examined the exercise-induced GH response to maximal sprint cycling at 
different pedaling rates by setting the resistance for the subjects at either 7.5% (fast) or 
10% (slow) of their body weight.  Despite similar peak and mean power output between 
the trials, peak GH and GH AUC following the fast sprint was more than twice as great 
as that after the initial slow sprint.  The exact mechanism for the increase in GH release 
due to faster pedaling rates is not known, but could be related to muscle activation 
suggesting there is a mechanical mechanism of localized muscle contraction involved in 
GH secretion and/or the result of increased frequency of neural firing during the fast trial 
as there was significant correlation between peak pedal revolutions and GH AUC (r = 
0.48, p < 0.05).  In the current study, peak power was greater in the first sprint of the 
SLEEP vs. SLD session; although the overall average across all four sprints was similar 
between sessions.  It is unlikely that the minor difference in exercise performance 
between the sessions allowed a signficant contribution of feedback to the neuroendocrine 
system (i.e. somatotropic axis) from the localized muscle activation.  Future research 
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needs to utilize experimental studies employing different muscle activation and 
purposeful differences in workload and the extent to which they can influence exercise-
induced GH release during sleep deprivation.   
The time to reach the peak GH concentration did not differ between sessions and 
was similar to previous reports using high-intensity sprint exercise (232-234).  
Considering that the time to reach peak GH concentration was similar between sessions 
suggests that the neuroendocrine response related to the onset of exercise appears 
unaffected by sleep deprivation.  Likely the large, acute stress of high-intensity exercise 
on the neuroendocrine system was sufficient to override any effects that sleep deprivation 
had on the system’s regulation.   However, data from exercise recovery suggests that the 
neuroendocrine systems related to recovery may be altered during sleep deprivation.  
During exercise recovery, GH typically returns to baseline within 2 hours regardless of 
aerobic or high-intensity exercise (213, 233, 287, 292-295).  In the current study, GH 
concentrations were significantly elevated compared to rest for 120-min post-exercise in 
both sessions (figure 4.3) compared to only 60 min post-exercise reported in the 
previously mentioned similar study using short-term, high-intensity exercise (1).  
However, Abedelmalek et al. (1) did not measure GH beyond 60-min.  We can’t 
conclude that short-term, high intensity exercise during sleep deprivation results in 
greater exercise-induced GH recovery times beyond 120-min post-exercise; however, our 
results suggest that during sleep deprivation, the exercise-induced GH recovery times 
may be prolonged and/or post-exercise GH concentrations may stay elevated for longer 
periods of time, partially explaining the enhanced total GH AUC during exercise and 
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recovery. The exact mechanisms related to this effect have yet to be elucidated, but we 
speculate that augmented GH release may be influenced by a de-sensitized autofeedback 
system at hypothalamic-pituitary axis (i.e. GH/IGF-1 axis) or the altered secretion of 
catecholamines, estradiol, cortisol, melatonin and/or cytokines during exercise recovery 
following sleep deprivation.   
GH release is mediated by hypothalamic and peripheral factors that facilitate a 
balanced integration of both positive and negative feedback communication to the 
pituitary gland.  Somatostatin (SMS) and growth hormone releasing hormone (GHRH) 
act antagonistically to regulate GH release from the hypothalamus, which in turn, affects 
GH release from the anterior lobe of the pituitary gland (276).  Furthermore, it has been 
demonstrated that SMS primarily regulates GH secretion from the pituitary and has little 
affect on GH synthesis.  Therefore, SMS does not initiate, but controls spontaneous GH 
secretion, unlike GHRH whose role has been tagged to the initiation of GH pulses (91).  
Hypothalamic GHRH outflow and SMS withdrawal is associated with increased GH 
release during SWS (64, 183).  However, GHRH-induced GH release is greatest at night 
and it has been reported that GHRH-induced GH release is reduced during sleep 
deprivation (260).  Regardless, other mechanisms must be involved in GH synthesis 
during sleep deprivation as indicated by the “supramaximal” release of GH stores by an 
exercise stimulus.   Together, the interaction of exercise somatostatinergic control of GH 
release suggests that 1) SMS regulation of GH release is tightly regulated during sleep 
deprivation, 2) GHRH-induced GH synthesis is not impaired during sleep deprivation 
and/or 3) other neural networks may provide additional inputs that alter GH synthesis and 
	  
108	  
	   	  
release.  We did not assess GHRH or SMS so results from the current study only can 
suggest that despite the speculated alterations in these two peptides, exercise can override 
their mechanistic influence to elicit a “supermaximal” GH release and thus, exercise is a 
very potent stimulator of GH release, even during sleep deprivation. 
Ghrelin can stimulate GH release by directly binding to the growth hormone 
secretagogue receptor type 1a (GHS-R1a) on the hypothalamus and/or the anterior 
pituitary while simultaneously providing negative feedback on hypothalamic SMS 
release (4, 11-12, 95, 116, 121, 137, 242-243).  Research supports that ghrelin must be 
involved for maximal exercise-induced GH release (61-62) and evidence that ghrelin has 
no effect on GH without GHRH activation suggests that the two may need to work 
synergistically to augment GH release (16).  Ghrelin appears to be associated most 
strongly with food intake and energy balance, perhaps to ensure that sufficient amounts 
of energy are available for GH to execute its biological effects rather than linkage to 
corresponding GH pulses (50, 106, 250, 254).  During fasting and partial sleep 
deprivation, ghrelin levels are elevated (50, 254, 264).  In the current study, we did not 
assess ghrelin, but we assume ghrelin was suppressed following the snack at 2000h, but 
likely started to elevate during the sleep deprivation session. It is possible that the 
synergistic effect of elevated ghrelin and exercise can augment the GH response 
following a night of sleep deprivation as stated previously. However, research has 
reported conflicting results on exercise-induced ghrelin concentrations under normal 
conditions (54, 142, 220, 236).  Considering the unequivocal exercise-induced grehlin 
reports coupled with the fact that diet was strictly controlled within subjects and between 
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sessions, it was unlikely that ghrelin played a key role in the exercise-induced GH 
response in the current study.  
Growth hormone exhibits its functional effects on adipose tissue by increasing 
lipid metabolism through increasing free fatty acid (FFA) and glycerol release from 
adipose tissue (59, 63, 67, 71, 96, 141, 173-174, 214, 278, 304).  Maximum FFA release 
has been linked to the ~120 minutes following peak nocturnal GH release and remains 
elevated ~5 hours post sleep-onset (217).  In the current study, FFA concentrations are 
unlikely to contribute to the exercise-induced differences in GH since FFA 
concentrations would have returned to baseline several hours prior to exercise in both 
sessions.  This is important, considering that FFA release suppresses GH release 
indirectly through suppression of GHRH or directly at the pituitary (120, 174).  
Furthermore, numerous studies support that exercise-induced GH increases in lipolysis 
from adipose tissue following, but not during exercise (96, 67, 71, 100, 173-174, 211).   
Thus, if FFA release was augmented following exercise, it was unlikely to suppress GH 
release via negative feedback during either session because FFA levels usually take 
several hours to peak following a substantial GH release and thus, negative feedback on 
GH release wouldn’t occur until much later.   
Of much greater physiological importance in the current study may be the 
“glycogen sparing” effect that has been theorized to be imposed by GH in several 
different tissues.  A shift in substrate utilization towards lipolysis in the presence of 
elevated GH suggests free fatty acids become the primary substrate utilized.  Thus, GH 
may function to maintain blood glucose concentrations, specifically for priority tissues 
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such as neuronal tissues in the brain.  It has been demonstrated that brain glucose uptake 
decreases during an upward shift in exercise intensity (132).   The relationship between 
GH and glucose sparing for sustained neuronal activity in the brain is not yet known, but 
the possible underlying mechanism necessary to provide adequate substrate for energy 
metabolism in the brain during sleep deprivation is an interesting theory that needs to be 
subsequently addressed.  
Few studies have evaluated the effects of brief sprint interval exercise on IGF-1; 
however, Meckel et al. (163) reported that GH levels increased with no subsequent 
change in IGF-1 up to one hour post-exercise after subjects completed 4 successive 
sprints similar to the current study.  However, IGF-1 has been shown to be unaffected 
during 3 nights of subsequent delta-wave sleep interruption (196).   Although studies 
have shown that GH/IGF-1 axis may be concomitantly influenced by exercise and/or 
sleep deprivation, the relationship between the two is multifaceted due to the complexity 
of experimental designs employing additional factors such as energy deficit and the large 
degree of IGF-1 molecular complexity (189).  For example, partial sleep deprivation has 
been shown to decrease total IGF-1 levels, but in combination with severe energy deficit 
caused by caloric deprivation and arduous physical activity (3).  In the current study, we 
controlled dietary intake so that it was standardized within subjects and between sessions 
with a focus on avoiding caloric restriction.  This may explain why free IGF-1 was 
unaffected by sleep deprivation or exercise in the current study.   IGF-1 is known to exert 
a negative long-loop, multilevel feedback effect on GH release (149).  One dimension of 
the loop directly inhibits IGF-1’s own production by inhibiting pituitary somatotrope 
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cells from producing GH.  The other loop alters GHRH and SMS release from the 
hypothalamus that also decreases GH production downstream at the pituitary.  Therefore, 
under normal conditions, a decrease in IGF-1 is associated with an increase in GH release 
mediated by SMS and GHRH hypothalamic tone (218, 260).   However, in the current 
study, free IGF-1 values were not influenced by exercise or sleep deprivation and 
therefore, IGF-1’s long-loop, multilevel feedback effect on GH release at the 
hypothalamic and pituitary levels was likely not a primary contributor to the enchanced 
GH response observed during SLD.  More research needs to be conducted on the primary 
effects of exercise during sleep deprivation on GH-mediated IGF-1 without the 
confounding effects of caloric restriction and negative energy balance.  
Our results demonstrate that short-term, high-intensity exercise is a very 
strenuous stimulus capable of enhancing GH release with or without sleep deprivation.  
While nocturnal GH release was not assessed in the current study, we assume that 
nocturnal GH release was minimal due to sleep deprivation.  Results support our 
hypothesis that short-term high-intensity exercise appears to override the sleep 
deprivation-induced mechanisms that blunt GH release, resulting in a “supermaximal” 
GH response when exercise follows sleep deprivation.  Metabolic effects of GH may 
potentially augment glucose availability for priority tissues, such as neuronal activity in 
the brain, during stressful states such as sleep deprivation, caloric restriction and negative 
energy balance.  Additionally, the ability of sleep deprivation to alter the exercise-
induced GH pulsatility profile could have substantial downstream GH-mediated 
biological effects during the days following these types of events.  When the innate sleep 
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schedule is disrupted, 24-h GH pulsatility is more sporadic and frequent “bursts” of GH 
released throughout a 24-h period transpires to make up for the significantly lower and 
unassociated GH pulse that occurs at sleep onset (35).   GH regulates fat metabolism, 
which influences body composition and insulin sensitivity.  It has been demonstrated that 
lipolysis is upregulated in the presence of larger intermittent but not smaller continuous 
GH infusion (148).   If in fact exercise during sleep deprivation does normalize GH 
pulsatility patterns, then humans with disrupted sleep schedules may benefit 
metabolically by exercising following sleep deprivation, creating a more uniform 
intermittent pulse of GH release vs. a more sporadic 24-hr GH release pattern.  These 
substantial downstream GH-mediated biological effects could lead to improvement in 
body composition, glucose tolerance or even muscle growth and repair for sleep-deprived 
individuals (i.e. students, athletes, doctors, nurses, parents of newborns).  
 In conclusion, we have demonstrated that exercise can override the attenuation of 
the GH release during sleep deprivation to elicit a “supermaximal” GH response and thus, 
exercise is a potent stimulator of GH release regardless of any mechanistic inhibition 
created by a holistic approach of GH-regulatory mediators confounded by complete sleep 
deprivation (i.e. somatotrophic hormones, catecholamines, estradiol, melatonin, 
cytokines, etc.) (112, 163, 191).  Future research should examine the interaction between 
exercise and GH release mediators during sleep deprivation as well as the capability of 
exercise to normalize 24-h GH pulsatility (and subsequent metabolic consequences) when 
normal sleep schedules are disrupted.   Additionally, little is known about the effects of 
the exercise-induced GH response during sleep deprivation and whether or not it “hyper-
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activates” an auto-negative feedback mechanism to suppress its own release throughout 
the day, so that total 24-hr GH AUC is similar to that of a 24-hr sleep-deprived session 
without exercise.  
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Table 4.1. Growth Hormone Concentration (M ± SEM).  
 
 Variable SLEEP SLD p Adjusted p** 
Resting GH (µg/L) 0.57 ± 0.13 1.35 ± 0.55 0.181 0.575 
Peak GH (µg/L) 17.8 ± 3.7 39.6 ± 7.1 0.002* 
 Time to Peak GH (min) 29.5 ± 2.2 27.0 ± 1.5 0.299 0.257 
ΔGH (µg/L) 17.2 ± 3.7 38.2 ± 7.3 0.003*   
#GH AUC (µg/L*min) 825.0 ± 199.8 2212.8 ± 441.9 0.001* 
  
#GH AUC during exercise and recovery only.  *p < 0.01.  **When data was non-
normally distributed, p values were adjusted for skewedness (>1.0) using the 
nonparametric Wilcoxon sign-ranked test. 
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Figure 4.1.  Experimental Protocol Showing the 24-Hr Laboratory Sessions.  The design 
was counter-balanced and randomized between sessions.   
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Figure 4.2.  Blood Draw Profile.  Samples were collected over 3-hours that included ~30 
minutes of resting metabolic rate (RMR) data collection and blood draws that occur every 
15 minutes on average, with more frequent sampling around the 13-minute exercise 
session.  BD = blood draw.  There were 17 blood draws in total.  
 
 
 
 
 
 
	  
117	  
	   	  
 
Figure 4.3.  Mean GH Concentrations at Each Time Point Between SLEEP and SLD 
Sessions During Exercise and Recovery.   The GH AUC data includes exercise that 
occurred at 0700 – 0713 (exercise onset occurred at time point 0) during the entire 3-hour 
profile.  Results of the repeated measures ANOVA indicated a significant interaction 
effect between time point and session (p < 0.05).  There were also significant main 
effects for time point (p < 0.01) and session (p < 0.05).  Wilcoxon signed-rank tests were 
used to further examine which average GH concentrations (by time point) differed 
between sessions.  Results indicated that exercise-induced GH concentrations were 
significantly lower during the SLEEP session from the onset of exercise (time point 0) 
through the remainder of the 120-minute profile a.  Additionally, exercise-induced GH 
values were significantly greater at each time point compared to resting GH values in 
both sessions and these remained greater throughout the entire 120-minute profile that 
included exercise and recovery b.  Furthermore, total GH AUC was significantly lower 
during the SLEEP session (p < 0.01)*.  
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Figure 4.4.  Individual (- - -) and Mean (―) GH AUC Between Sessions. 
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Figure 4.5. Individual (- - -) and Mean (―) Peak GH Concentration Between Sessions. 
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Figure 4.6. Free IGF-1 Response Pre- and 90 Minutes Post-Exercise Between Sessions.  
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CHAPTER V 
 
GENERAL DISCUSSION 
 
 
 The primary purpose of this dissertation was to assess the impact of acute sleep 
deprivation on exercise-induced GH release.  Secondary aims were to investigate 
alterations in exercise performance and cognitive function during acute sleep deprivation.   
Literature suggests that sleep deprivation can impair exercise performance and 
cognition.  However, this literature is equivocal, largely the result of varying exercise 
protocols, cognition tests, populations and experimental designs.  Additionally, many of 
these protocols are incremental and progressive in nature and thus, subjected to the 
confounding influences of central (mental, i.e. motivation) and peripheral (physical, i.e. 
neuromuscular activity, substrate availability) fatigue. 
There are many situations where sleep is disturbed prior to and/or during an 
athletic, occupational or academic event.  These events require peak performances in 
exercise and/or cognition.  In these situations, the question arises as to 1) what particular 
forms of exercise and/or cognition are affected by sleep deprivation and 2) does exercise 
counteract sleep deprivation’s effect on cognition?  Chapter III presents information from 
this study on the impact of acute sleep deprivation on exercise performance and 
cognition.  The major findings were 1) anaerobic power was unaffected by sleep 
deprivation with the exception of peak power during the first Wingate test, 2) heart rate 
was significantly reduced during rest and exercise following sleep deprivation but was 
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not related to overall exercise performance, and 3) psychomotor sensory sensitivity, but 
not cognitive processing capability, worsened after exercise during sleep deprivation.   
We hypothesized that sleep deprivation would impair exercise performance. 
Previous literature reported that neuromuscular activation and maximal voluntary muscle 
contraction during an exercise test to exhaustion was unaffected by 24-hr of sleep 
deprivation.  Whether or not sleep deprivation influenced the muscle cell’s ability to 
generate energy (ATP) from phosphocreatine during the first five seconds of maximal 
voluntary muscle contraction during the Wingate test (relating to peak power) is 
unknown and would be difficult to associate as a probable cause without measuring 
nucleotide presence and enzymatic activity levels immediately pre- and post-exercise.  
However, sleep deprivation can create a negative energy balance leading to impairments 
in muscle contraction and membrane potential, although the extent to which these effects 
occur are likely to be largely influenced by metabolism, fitness of the individual and 
experimental design.  Further research needs to examine the effects of sleep deprivation 
on the ATP-PC system in the muscle and its associated effects on muscle contraction and 
substrate availability during peak anaerobic exercise.   
The peak exercise-induced HR response was ~6 bpm lower during sleep 
deprivation, even though combined work was similar.  The reason for a lower HR 
response during exercise following sleep deprivation is likely multifaceted and 
complicated.  Sleep deprivation may override the neural input (adrenergic, cholinergic, 
dopaminergic) during submaximal exercise per se, but to our knowledge, no one has 
reported the effects of sleep deprivation on neural input during short-term, high-intensity 
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exercise.  Considering that heart rate was lower at rest and respiration rate was 
reciprocally elevated during sleep deprivation suggests that the ventilatory drive that 
influences heart rate may be altered by sleep deprivation at rest.   Although lower 
sympathetic drive (lower plasma catecholamine levels) may also suggest a lower resting 
heart rate during sleep deprivation, it can’t explain why strenuous exercise could not 
“jumpstart” sympathetic drive as it does following a night of adequate rest, similar to 
respiration rate.  
Very little research has approached the idea of purposely using exercise to 
counterbalance the detrimental effects of sleep deprivation on cognitive function. We 
hypothesized that cognitive function would be detrimentally affected by sleep 
deprivation, but high-intensity exercise would counterbalance the effect of sleep 
deprivation so that cognition would slightly improve following exercise.  However, our 
results indicated that sleep deprivation had no effect on psychomotor sensory sensitivity 
at rest based on the measures taken, indicating that sleep deprivation by itself may not be 
enough to cause a lack of sensory degradation.   However, the exhaustive exercise 
protocol actually worsened reaction time during the PVT test.  These results could 
indicate that the strenuous exercise protocol used in the current study could have had an 
interaction effect with sleep deprivation and the decline in PVT performance may have 
been a direct result of the peripheral (neuromuscular) and central (substrate availability 
for neuronal activity) fatigue. 
The primary purpose of the study was to examine the impact of acute sleep 
deprivation on exercise-induced GH release and these results were discussed in Chapter 
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IV.  Knowing that nocturnal GH release is attenuated during sleep deprivation, we 
hypothesized that strenuous exercise in sleep-deprived subjects would elicit a 
“supramaximal” GH response.  Our primary findings confirm that short-term, high-
intensity exercise is a very strenuous stimulus capable of enhancing GH release with or 
without sleep deprivation; however, exercise-induced GH AUC and peak GH 
concentration were significantly greater during sleep deprivation.  The exact mechanisms 
related to the augmented exercise-induced GH release during sleep deprivation have yet 
to be elucidated, but we speculate that it may be influenced by a de-sensitized 
autofeedback system at the hypothalamic-pituitary axis (i.e. SMS, GHRH, ghrelin, etc.) 
or the altered secretion of catecholamines, cortisol, melatonin and/or cytokines.  
However, the neuroendocrine factors associated with the onset of exercise appear to be 
unaffected by sleep deprivation since the time to reach peak GH concentration did not 
differ.  
Although GH remained signifcanlty elevated post-exercise during sleep 
deprivation, we can’t conclude that short-term, high intensity exercise during sleep 
deprivation results in greater exercise-induced GH recovery times beyond 120 minutes 
post-exercise; however, we can speculate that during sleep deprivation, the exercise-
induced GH recovery times are extended beyond the normal recovery times previously 
observed following exercise bouts.  Future research needs to examine the affect of 
exercise during sleep deprivation on the entire subsequent 24-hr GH pulsatility release 
patterns.  This could have substantial downstream GH-mediated biological effects; 
especially since 24-h GH pulsatility is more sporadic during sleep deprivation.  Since the 
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pulsatile pattern of GH secretion, and not the total concentration, favors GH bioactivity, 
we need to examine if exercise during sleep deprivation can “normalize or re-set” GH 
pulsatility patterns.  Additionally, little is known about the effects of exercise-induced 
GH release during sleep deprivation and whether or not it “hyper-activates” an auto-
negative feedback mechanism to suppress its own release throughout the day, so that total 
24-hr GH AUC is similar to that of a 24-hr sleep-deprived session without exercise.  
Thus, humans with disrupted sleep schedules may benefit metabolically by exercising 
following sleep deprivation, creating a more uniform intermittent pulse of GH release vs. 
a more sporadic 24-hr GH release pattern. The downstream GH-mediated cellular effects 
are substantial and could lead to improvement in body composition, glucose tolerance or 
even muscle growth and repair for sleep-deprived individuals.   
In conclusion, anaerobic exercise performance is only slightly influenced by sleep 
deprivation.  Initial peak performance was impaired, but throughout a bout of successive 
anaerobic exhaustive tests, the mean anaerobic performance was similar, regardless of an 
attenuated exercise-induced peak HR response.  This suggests that performance in sleep-
deprived athletes should not be affected in athletic events or training that require primary 
utilization of the ATP-PC and glycolytic system.  However, coaches and trainers should 
be aware of the lower HR response to high-intensity exercise in sleep-deprived athletes 
and make adjustments if using HR as criteria for exercise monitoring and prescription.    
It also appears that the normal linear relationship between exercise workload and 
exercise-induced GH release is exacerbated during sleep deprivation.  This means more 
GH release can occur without a subsequent increase in total exercise workload during 
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sleep deprivation. This suggests that sleep-deprived persons (medical call staff and other 
medical personnel, shift workers with alternating day/night work schedules and 
transmeridian travelers) might benefit from short-term, high-intensity exercise following 
a night of disrupted sleep.  Additionally, the augmented exercise-induced GH release 
during sleep deprivation may have an effect on subsequent 24-hr GH pulsatility profiles 
and this may have beneficial downstream metabolic effects.    
Finally, psychomotor sensitivity was not impaired by 24-hr of sleep deprivation, 
but it was impaired following high-intensity exercise and is likely the result of an 
interaction between central and peripheral factors.  This suggests that short-term, high-
intensity exercise during sleep deprivation is not a recommended method for enhancing 
psychomotor sensory sensitivity.  Coaches should be aware that athletes participating in 
high-intensity athletic events or training will have decreased reaction time that could lead 
to impairments in skill-related performance or injury as a result of improper technique 
caused by delayed sensory sensitivity.   
Our results are limited by the confounding effects of the circadian rhythm and the 
sleep-wake cycle on GH release.  Although disturbances in the inherent circadian rhythm 
or sleep behavior can both alter GH release, the currently available literature strongly 
supports the role of sleep behavior over circadian rhythm in regards to GH release.  
Regardless of the difficulty in examining circadian rhythm and sleep deprivation 
separately and the complications in extrapolating the hormonal release results, the exact 
mechanisms influencing GH response following acute sleep deprivation are largely 
unknown.  Due to the limited reports on the effects of circadian rhythm on growth 
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hormone release, the aim of the current study was to examine acute sleep deprivation and 
its practicality to the sleep-deprived athlete or adult working population.  Thus, our 
subjects were kept awake in a well-lit environment similar to what they would experience 
during the biological daytime hours.   
The second limitation to our study is that we did not record sleep stages or 
monitor brain activity during the night of sleep in the lab.  Since GH release is highly 
correlated with SWS, we do not know how much SWS our subjects attained while 
sleeping in the laboratory.  This could have influenced the amount of nocturnal GH and 
have a subsequent effect on exercise-induced GH release the following morning.  During 
the sleep deprivation session, we did constantly monitor our subjects and focused on 
social interaction during the sleep deprivation night.  Additionally, we used the Epworth 
Sleepiness Scale to screen for sleep disorders prior to testing and also recorded self-
reported sleep perception from our subjects.  We found no differences in sleep habits or 
self-reported quality of sleep.  
The third limitation to our study is that we didn’t measure nocturnal GH 
concentration and can only speculate that it was unaltered during the sleep session and 
attenuated during sleep deprivation based on previous research.  Furthermore, we did not 
measure GH concentrations and brain activity during the rest of the day following the 
exercise protocol.  Literature suggests that the attenuated GH release following sleep 
deprivation can be partially counterbalanced by an augmented GH release the following 
day, even if sleep doesn’t occur. However, no studies have examined the effects of 
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exercise-induced GH release on increasing total GH release the day following sleep 
deprivation.  
A fourth limitation to our study is that we didn’t measure GH secretory dynamics 
during exercise and recovery.  Literature suggests that the pulsatility of GH release is 
more important than the total concentration in mediating the downstream biological 
effects of GH.  Several studies have reported that GH pulsatility is altered the day after 
sleep deprivation, but no studies have examined the effect of short-term, high-intensity 
exercise following sleep deprivation on subsequent 24-hour GH release or secretory 
dynamics. Without measuring secretory dynamics, we can only speculate that a change in 
total GH concentration is accompanied by a change in GH secretory dynamics.  
 Finally, our study was limited by using a single sleep cycle disturbance. 
Additional sleep disturbances might have a greater effect on exercise performance, 
hormone response and/or cognition.  
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APPENDIX A 
 
UNIVERSITY OF NORTH CAROLINA AT GREENSBORO CONSENT TO ACT AS A 
HUMAN PARTICIPANT 
 
 
Project Title:  Effect of Acute Sleep Deprivation on Exercise-Induced Growth Hormone Release 
Primary Investigator:  Laurie Wideman, PhD 
Project Director: Kevin Ritsche 
Participant's Name:      
 
WHY ARE WE DOING THIS STUDY? 
We are interested in determining the effects of acute sleep deprivation on release of human 
growth hormone during exercise.   
WHO IS ELIGIBLE TO PARTICIPATE: 
You are eligible to participate in this study if you are currently physically active but participate in 
less than 10 hours per week of recreational activities (swimming, basketball, jogging, cycling 
etc.).  You must be a male between the ages of 18 – 30.  You must not be involved in any sprint 
(interval) training and also be a non-smoker (have not smoked within the previous 3 months).  A 
complete list of exclusionary criteria includes the following: 
• due to the effect of training on GH secretion during exercise, individuals who have 
engaged in any type of sprint training program in the last 6 months 
• due to the reported effect of obesity attenuating GH secretion during exercise, individuals 
who are classified as obese via a BMI ≥ 30 
• due to the menstrual cycle induced differences in GH secretion, all individuals who are 
female 
• individuals who are unable to perform exercise due to physical and/or orthopedic 
limitations 
• individuals who are currently on a caloric restriction program (diet) or taking any 
medications that promote weight loss 
• individuals who have used regularly used tobacco products within the last 3 months 
• individuals who are currently taking medications that would affect endocrine function 
• individuals with clinically-documented GH-deficiency  
• due to the effect of transmeridian travel on circadian rhythm, those individuals who have 
completed transmeridan travel in the last month 
• individuals with documented sleep disturbances or irregular sleeping patterns 
(occupational or recreationally-related)  
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WHAT YOU WILL BE ASKED TO DO IF YOU PARTICIPATE IN THIS STUDY:  This 
study will include approximately 10 subjects and will involve approximately 50 total hours of 
your time.  If you agree to participate in the study, these are the things that we will be asking you 
to do: 
 
• Come into the WSSU Exercise Science Laboratory to practice riding the stationary 
bicycle and fill out the medical questionnaire. 
• A whole body scan will be used to determine your body composition.  The scan will be 
completed in the Exercise Science Laboratory on the Winston-Salem State University 
campus.  You will lay flat on an x-ray table and the scanner will move back and forth 
several feet above you.  Depending on your height, the entire procedure takes 
approximately 15-20 minutes.  
• Come into the WSSU Exercise Science Laboratory on two separate 24-hour sessions.  On 
one occasion you will be allowed to sleep within the lab for 8 hours.  On the other 
occasion, you will be asked to stay awake the entire night.   
• During both sessions, you will have a catheter inserted into your arm by a trained 
technician that will allow us to draw a small amount of blood (170) for three hours in 
approximately 15-minute intervals.  The total amount of blood drawn in one session is no 
more than you would normally give if you donate blood.  This will occur in the morning 
following a night of sleep or staying awake. 
• Perform a series of four short 30-second all out sprints on a stationary bike the morning 
following your session.  
 
POTENTIAL RISKS AND DISCOMFORTS: 
  
There are minor risks that are possible as a result of participating in this study.  These 
include muscle fatigue and dizziness during and after the exercise, abnormal changes in heart 
function, and, in very rare instances, heart attack (non-fatal or fatal) may also occur during the 
exercise test. However, the American College of Sports Medicine (2006) has provided the 
following information regarding this risk:  The incidence of sudden cardiac death during vigorous 
exertion in healthy adults is estimated at one death per year for every 15,000 to 18,000 
individuals.  The overall risk of exercise testing in a mixed subject population is approximately 
six cardiac events (e.g. heart attack, dangerous irregular heartbeat, or death) per 10,000 
tests.  These are all conditions that would require immediate medical attention.  In the unlikely 
event of an emergency, the investigator will provide Cardio-Pulmonary Resuscitation (CPR) 
and/or administer an Automatic External Defibrillator (AED) if appropriate and will call 911 for 
emergency assistance.  
Infection is possible when blood samples are taken, but the risk of infection will be 
minimized through the use of sterile techniques by a trained technician. Only slight discomfort 
should occur. You should feel slightly more pain than a mosquito bite when the catheter is placed. 
Bruising may occur following catheter placement and may result in mild-to-moderate soreness to 
the touch for several days.  The total amount of blood that will be taken during the course of the 
entire study is 35 ml.   
You will be exposed to a very mild radiation from the DXA body composition scan.  This 
mild radiation is equivalent to 1/10 the exposure from a routine chest x-ray, and less than the 
exposure of a dental x-ray.  The radiation amount combined from both DXA body composition 
scans will be less than 2/10 the exposure from a routine chest x-ray. 
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POTENTIAL BENEFITS: 
 
This study is significant as it aims to make a change in the current trends of fighting the 
battle against metabolic-related diseases related to altered sleep patterns (i.e. sleep disorders, shift 
work).  The benefit of enhancing GH secretion amidst altered sleep patterns may aid in the 
development of lean muscle mass production or prevention of post-exercise hypoglycemia and/or 
increased lipolysis resulting in decreased fat mass and increased lean body mass.  Increased 
amount of lean muscle mass may delay or even prevent the progression of metabolic disorders 
resulting from excess amounts of body fat through increased resting energy and caloric 
expenditure. 
 
COMPENSATION FOR PARTICIPATION:   
 
You will be paid the sum of $100.00 upon full completion of this study.  
 
COMPENSATION/TREATMENT FOR INJURY:  
 
There is no compensation for any physical or psychological events that may result from 
your participation.  Please contact Mr. Eric Allen at (336) 256-1482 if you sustain any research-
related injuries. 
 
RIGHT TO WITHDRAW:   
 
You are free to withdraw from this study at any time. If you decide to withdraw from 
this study you should notify the research team immediately. The research team may also end 
your participation in this study if you do not follow instructions, miss scheduled visits, or if your 
safety and welfare are at risk. 
 
CONFIDENTIALITY:   
 
The information that is obtained from this study will be handled with confidentiality.  
Only authorized individuals of the research team will have access to all research data that is 
stored securely in a confidential file in the Exercise Science Laboratory.  You will be assigned a 
subject number and all data will be identified by this number.  The list connecting your name to 
this number will be kept in a locked file and/or on a laptop computer that is password protected 
with encryption software.  Any information derived from this research project that personally 
identifies you will not be voluntarily released or disclosed by these entities without your separate 
consent, except as specifically required by law.  Research records provided to authorized, non-
WSSU entities will not contain identifiable information about you.  Publications and/or 
presentations that result from this study will not include identifiable information about you. The 
researchers intend to keep the research data in a repository indefinitely. Other researchers will 
have access to the data for future research; however, the list connecting your name to your subject 
number will be destroyed after the current research team has completed their analysis of your 
data.  Finally, your blood samples obtained for the purposes of this study will become the 
property of Winston-Salem State University.  Once you provide the blood specimens you will not 
have access to them.  The specimens will be discarded or destroyed once they have been used for 
the purposes described in the protocol. 
	  
162	  
	   	  
SUBJECT CONSENT STATEMENT 
 
By signing this consent form, you agree that you understand the procedures and any risks 
and benefits involved in this research.  You are free to refuse to participate or to withdraw your 
consent to participate in this research at any time without penalty or prejudice; your participation 
is entirely voluntary.  Your privacy will be protected because you will not be identified by name 
as a participant in this project. 
The University of North Carolina at Greensboro Institutional Review Board, which 
ensures that research involving people follows federal regulations, has approved the research and 
this consent form.  Questions regarding your rights as a participant in this project can be 
answered by calling Mr. Eric Allen at (336) 256-1482.  Questions regarding the research itself 
will be answered by Kevin Ritsche by calling336-750-3310.  Any new information that develops 
during the project will be provided to you if the information might affect your willingness to 
continue participation in the project. 
By signing this form, you are affirming that you are 18 years of age or older and are 
agreeing to participate in the project described to you by Kevin Ritsche. 
 
____________________________________   ______________ 
Participant's Signature*       Date  
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APPENDIX B 
 
PHYSICAL ACTIVITY QUESTIONNAIRE 
 
 
Subject ID#   
   
Question #1: In general, compared to other persons your age, rate how physically fit 
you are: 
 
1   2    3     4     5       6         7         8           9       10 
 
Not at all fit    Somewhat fit    Extremely fit 
 
 
Question #2: How often do you engage in sprinting or high-intensity training? 
 
□ 5 or more times per week      □ 4 times per week  □ 3 times per week  
□ 2 times per week            □ 1 time per week  □ Never/only occasionally 
 
Question #3:  How many hours do you participate in recreational activities per week 
(swimming, basketball, jogging, cycling, etc.)? 
 
□ < 2 hours per week            □ 2-4 hours per week  □ 4-6 hours per week 
□ 6-8 hours per week            □ 8-10 hours per week  □ > 10 hours per week 
 
 
Question #4: How much hard physical work is required on your job? 
□ a great deal   □ a moderate amount  □ a little □ none 
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APPENDIX C 
 
SLEEP LOG 
 
 
 
 
 
 
 
 
 
 
 Fell 
asleep 
Woke 
up 
How awake 
did you feel 
during day 
(1-
exhausted 
to 5-wide 
wake) 
Time of 
last meal 
before 
bed 
Anything unusual in 
your sleep? 
 
Day 1 
     
 
Day 2 
     
 
Day 3 
     
 
Day 4 
     
 
Day 5 
     
 
Day 6 
     
 
Day 7 
     
24-HOUR  
SESSION 
     
	  
165	  
	   	  
APPENDIX D 
 
EPWORTH SLEEPINESS SCALE AND SLEEP DISORDER QUESTIONNAIRE 
 
 
How likely are you to doze off or fall asleep in the following situations in contrast to just 
feeling tired?  Even if you have not done some of these recently, try to work out how they 
would have affected you.  Use the following scale to choose the most appropriate number 
for each situation.   
In order for the questionnaire to be valid, you must answer all of the questions.  Please do 
not cross out or alter any of the questions.  
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
 
SITUATION: 
1 Sitting and reading:  
2 Watching TV:  
3 Sitting inactive in a public place (i.e. a theater or 
meeting) 
 
4 As a passenger in a car for an hour without a 
break: 
 
5 Lying down to rest in the afternoon when 
circumstances permit 
 
6 Sitting and talking to someone:  
7 Sitting quietly after lunch without alcohol  
8 In a car, while stopped for a few minutes in 
traffic 
 
        EPWORTH TOTAL: 
 
If the results are <10, the participants are less likely to have daytime sleepiness and 
intrinsic sleep disorders, while ESS scores > 10 are effective in identifying patients that 
snore, have obstructive sleep apnea syndrome (OSAS) and their associated 
cardiovascular and cerebrovascular health risks, as well as other intrinsic sleep 
disorders such as insomnia, idiopathic sleep hypersomnia and narcolepsy.  
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Body Mass Index Questions (BMI): 
9 What is your height in total feet and inches?  
10 What is your weight?   
 
Sleep Disorder History Questionnaire 
11 Have you ever been diagnosed with any of the 
following ISDs?  Please circle all that apply:  
          1.  insomnia 
          2.  hypersomnia 
          3.  narcolepsy 
          4.  periodic limb          
             movement disorder          
           5.  restless leg  
           syndrome        
           6. obstructive sleep       
           apnea      
           7. central sleep    
           apnea 
Other: 
 
12 Are you currently being treated for any of the 
above sleep disorders? 
Yes        No      N/A 
13 Are you currently using a CPAP machine, dental 
device or undergone surgery for treating sleep 
disorders? 
Yes        No      N/A 
14 Do you on a regular basis have a strong urge to 
move your legs; sometimes with unpleasant 
feelings in your legs that start or get worse when 
you’re inactive, increasing when you’re sitting 
still or lying down and resting, with movement 
helping to relieve the unpleasant feelings that 
start or get worse in the evening or at night?  
Yes        or        No       
 
STOP Questionnaire 
15 S:  Do you snore loudly? Yes        or        No       
16 T:  Do you often feel tired, fatigued, or sleep 
during the daytime?  
Yes        or        No       
17 O:  Has anyone observed you stop breathing 
during sleep?  
Yes        or        No       
18 P:  Do you have or are you being treated for high 
blood pressure?  
Yes        or        No       
TOTAL YES:   
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APPENDIX E 
 
FATIGUE SEVERITY SCALE (FSS) 
 
 
The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue on you.  
The FSS is a short questionnaire that requires you to rate your level of fatigue.  The FSS 
questionnaire contains nine statements that rate the severity of your fatigue symptoms.  
Read each statement and circle a number from 1 to 7 based on how accurately if reflects 
your condition during the past week and the extent to which you agree or disagree that 
the statement applies to you.  
 
A low value (e.g., 1) indicates strong disagreement with the statement, whereas a 
high value (e.g., 7) indicates strong agreement. 
 
19 My motivation is lower when I am fatigued  
20 Exercise brings on my fatigue  
21 I am easily fatigued  
22 Fatigue interferes with my physical functioning  
23 Fatigue causes frequent problems for me  
24 My fatigue prevents sustained physical 
functioning 
 
25 Fatigue interferes with carrying out certain duties 
and responsibilities 
 
26 Fatigue is among my three most disabling 
symptoms 
 
27 Fatigue interferes with my work, family, or 
social life 
 
              FSS TOTAL:  
37 or more may be a sign of fatigue 
  
28 If Applicable:  After taking this screening test, 
do you feel that you might research the issue 
further with your regular physician?  
Yes        or        No       
29 If Applicable:  If you have been diagnosed with 
a sleep disorder, please rate on a scale of 1 to 5 
how effective you feel that the your treatments 
have been (5 being very effective, 1 not being 
effective) 
 
30 Do you work 24 hour or 12 hour night shifts?  Yes        or        No       
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Results:  If the results of the ESS scores are > 10, and/or the results of the STOP 
questionnaire equal 2 or greater, then you may be predisposed to intrinsic sleep 
disorders.  Follow-up with your physician is recommended.  If you score a 37 or more on 
the FSS questionnaire, then you may instead be suffering form fatigue from SWSD and 
the results of the ESS or STOP questionnaires would be inconclusive.  In either case, an 
overnight polysomnogram is the best methods for diagnosing ISD’s.   
 
 
 
 
 
 
 
